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ABSTRACT 
Unique to survival analysis of veterinary clinical data is classification of 
observations from euthanized animals. The first study highlighted limitations of 
Kaplan-Meier product limit analysis (KM) of veterinary clinical data. Three data sets 
with different outcome proportions (alive, lost-to-follow-up, dead due to disease, dead 
due to other, euthanized due to disease, euthanized due to other) were used. Different 
classifications of observations from euthanized animals caused inconsistent 
conclusions of significant differences between strata within data sets. At times, 
ranking of median survival time estimates for strata was reversed.  The KM was found 
inappropriate to evaluate observations from euthanized animals. This finding, coupled 
with restriction of KM to two-state description of disease (alive to outcome), prompted 
exploration of an alternate analysis method.   
Markov models allow modeling of multiple health states and outcomes. A 5-
state, time-homogeneous, Markov chain was used for a cohort of 64 dogs with 
generalized lymphoma. The model contained two transient (WELL, TOXIC) and three 
absorbing  (DEAD, EUTHANASIA, LOST-TO-FOLLOWUP) states. The transition 
probability matrix (P) was used to iterate future transitions and survival probabilities. 
Matrix solution and Monte Carlo simulation were used to estimate survival time. 
Estimates appeared reliable.  
Markov modeling was extended for comparison of vaccine-associated sarcoma 
progression after treatment in a cohort of 294 cats. For a 5-state model, transition 
probabilities derived from exponential transformation of incidence rates were used to 
 xii 
 xiii 
construct P for each treatment – NONE (no surgery), SX (surgery) and SX+RAD 
(surgery and radiation). Monte Carlo estimates of durations in transient states and 
expected survival showed SX+RAD prolonged expected survival significantly longer 
than SX than NONE.  Commitment to repeated treatment with surgery and radiation 
did prolong expected survival of cats with vaccine-associated sarcoma.   
Assumptions of Markov modeling did not appear prohibitive for analysis of 
veterinary clinical data and further exploration is warranted.  
 
 
 
 
 
CHAPTER 1 INTRODUCTION/LITERATURE REVIEW  
 1 
1.1 Introduction: Definition of the Clinical Epidemiology Problem 
Veterinary studies investigating clinical disease are usually directed at testing 
hypotheses of treatment protocols or identifying prognostic factors.  The question of 
interest is often whether the probability of success is greater with one treatment than 
with the other, or with the presence of one characteristic versus another. Success for 
most of these studies is survival.  Survival is however, an unrestricted end point and 
survival must be estimated indirectly from the occurrence of death.  Thus, the outcome 
of interest for these studies becomes death.  
Scrutiny of the veterinary literature over the last 10 years shows investigators 
almost exclusively use Kaplan-Meier product limit estimation for evaluation of time-
event data (Thompson and Fugent, 1992, Al-Sarraf, et al., 1996, Blackwood and 
Dobson, 1996, Kuntz, et al., 1997, Levy, et al., 1997, Dunning, et al., 1998, Khanna, et 
al., 1998). These methods are simple and make efficient use of truncated or censored 
data (Hillis, et al., 1986).  They are restricted by assumptions of  non-informative 
censoring and limit the description of disease to permanent transition from one state 
(alive) to another (dead).   
Many clinical studies involve complex changes other than death, for example, 
relapse, recurrence, recovery, and remission. Investigators will force this complexity 
to fit with Kaplan-Meier methods by evaluating time to recurrence or relapse (Hillis, 
et al., 1986). This fragments the investigation and if explored out of context with other 
outcomes, results in incomplete evaluation of the data.  
Veterinary clinical studies pose a unique situation since many subjects in these 
studies are euthanized.  Veterinary studies include a high frequency of euthanized 
 2 
subjects, sometimes over 50% of the total observations are from euthanized animals 
(Cox, et al., 1991, Berg, et al., 1992, Munana and Luttgen, 1998, Zwahlen, et al., 
1998).  While death remains the outcome of primary interest in such studies, 
investigators are inconsistent in their attention to euthanasia. Investigators have 
ignored, deleted, censored or simply equated with death any observation that 
terminates in euthanasia (Al-Sarraf, et al., 1996, Kuntz, et al., 1997, Dunning, et al., 
1998, Khanna, et al., 1998).  Other investigators acknowledged that euthanasia posed 
an analytical problem (Slater, et al., 2001, Staatz, et al., 2002) but chose to ignore the 
problem and equated euthanasia with death. One investigator considered it imposed 
normal variation into analysis of veterinary studies (Slater, et al., 2001) while the other 
proposed there was justification for exclusion of these observations but did not 
substantiate this statement (Staatz, et al., 2002).  
The decision to euthanize an animal is based on several factors that include the 
health of the animal, age of the animal and cost of the treatment (Gobar, et al., 1998, 
Mallery, et al., 1999). Thus, euthanasia should be identified as an outcome of 
secondary interest. Euthanasia can be recognized as a censored observation since it 
will cause some subjects to fail before they reach the outcome of interest (Lagakos, 
1979).   
Unfortunately, simply censoring the observations from euthanized animals is 
not appropriate. Euthanasia may be unrelated to the disease of interest. However, in 
most situations, the time of euthanasia offers some information on the time of death 
and the observations are informative. Euthanasia also represents a competing risk 
(Lagakos, 1979).  The objective for most competing risks is to estimate the time of 
 3 
failure from a particular cause when other causes of failure are not in effect.  However, 
for euthanasia, the complete observation of the survival time of interest is an 
unachievable event (Lagakos, 1979). 
 Thus, two limitations of conventional survival analysis methods currently used 
for investigation of veterinary clinical studies become apparent; 1) they are inadequate 
to describe the complexity of disease beyond two simple states of alive or dead (or 
some isolated intermediate endpoint), and 2) they are inadequate to handle the 
complicated issue of observations from euthanized animals.  
An alternate strategy to describe and evaluate time-event data is the use of 
Markov models. A Markov model is a stochastic model (one which models random 
events) used in diverse fields such as computer science, engineering, mathematics, 
genetics, agriculture economics, education and biology (Hillis, et al., 1986, Jain, 1986, 
Stewart, 1994).  Markov models have been used to describe human disease processes, 
for example, the evaluation and description of diabetic retinopathy (Marshall and 
Jones, 1995), systemic lupus erythematosus (Silverstein, et al., 1988), renal disease 
(Schaubel, et al., 1998), papilloma virus and human immunodeficiency virus 
(Hendriks, et al., 1996).   
Markov models can be used to describe disease as a series of probable 
transitions between health states.  This methodology has considerable appeal for use in 
veterinary clinical studies since it offers a method to evaluate multiple health-states 
simultaneously.  In addition, it potentially offers a method to accommodate 
observations from euthanized animals by recognizing euthanasia as a concurrent 
outcome of interest.   
 4 
Markov models of veterinary clinical disease have not been described.  This 
investigation highlighted the limitations of Kaplan-Meier product limit methods for 
time-event data in veterinary clinical studies, explored the application of a Markov 
model for a veterinary clinical data set and used a Markov model to describe and 
estimate expected survival in a veterinary clinical cohort.  
1.2 Markov Models Overview 
Markov modeling is a form of stochastic modeling that describes a process as a 
series of probable transitions between states. For example, the natural course of a 
disease can be viewed for an individual subject as a sequence of certain states of 
health (Beck and Pauker, 1983).  A Markovian stochastic process is memory-less.  
Knowledge of the current state is sufficient to predict what the future state will be and 
is independent of where the process has been in the past. This characteristic is also 
described as the (strong) Markov property (Norris, 1997).  
The Markov process can be classified according to characteristics of the state 
space being measured. A discrete or finite space is assumed for most purposes and 
implies there is a finite number of states that will be reached by the process (Jensen 
and Bard, 2002a).  A continuous or infinite process is possible.  The Markov process 
is also classified according to the time intervals of observation of the process.  
Processes may be observed at restricted or discrete intervals or can be observed 
continuously (Kempthorne and Folks, 1971).   
The term Markov chain is used to describe a process observed at discrete 
intervals. A Markov process described a process observed continuously. Some 
investigators prefer to describe Markov chains as a special case of a continuous time 
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Markov process, that is, the process is really a continuous-time Markov process, only 
it is observed at discrete intervals (Marshall, 1990). The term Markov process can thus 
be used to collectively describe all processes and chains.  
Another important distinction of Markov processes is that of time 
homogeneity.  When the transition probabilities are constant regardless of the time of 
observation, the process is time-independent or time homogenous (Beck and Pauker, 
1983) and the distribution of the number of transitions into a state follows a 
homogenous or stationary Poisson process. The Poisson distribution is described as 
Pr{ ( ) } ( ) !k tN t k t e kλλ −= =  where λ is the average number of transitions per period t  
(or the rate of arrivals) over k cycles  (Jensen and Bard, 2002b).  The time between 
transitions in a homogenous Poisson process follows an exponential distribution 
defined by the same parameter λ (Meeker and Escobar, 1998a).  
Time homogeneous Markov chains best describe short-term medical problems 
in people. Time non-homogeneous models may better describe chronic disease in 
people  (tens of years) since other factors such as age influence the transition 
probabilities and cause them to be time-dependent (Beck and Pauker, 1983). Markov 
models can be generalized to observations made at regular time intervals, at irregular 
time intervals, or where observations are made at irregular intervals but the exact time 
of transition during that interval is not known (Marshall, 1990). 
1.3 Discrete Time Markov Chain 
Consider the time-homogenous model where the transition probabilities are 
constant over time. The transition probability matrix P(t) contains the probabilities for 
the transitions.   Since the probabilities for the time-homogenous model are constant, 
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the probability matrix could simply be written as P (Figure 1-1). The rows represent 
the current health state and the columns represent the future state. The probabilities are 
described as pij where p is the probability of moving from state i  to state j for any 
given cycle. 
11 12 13
21 22 23
31 32 33
1 2 3
1
2
3
p p p
p p p
p p p
   =     
P
 
Figure 1-1 Probability transition matrix for a time homogeneous 3-state Markov 
model. 
 
The sum of the row probabilities equals one since each health state is 
independent of the other and an animal must move to one of the three states.  The 
diagonals represent the probability of staying in the same health state.  A state is 
considered absorbing when the probability of leaving a state is zero. For example, 
being dead is an absorbing state. 
1.4 Continuous Time Markov Process 
The transition between states is viewed as a rate for a continuous-time Markov 
process.  The transition rate does not depend on the length of the observation interval 
since it is the number of transitions that occur per unit time.  The transition intensity 
(rate) matrix Q(t) contains components qij which are transition rates from state i to j. 
Since the rates for a time-homogenous Markov process are constant, the rate matrix 
could simply be written as Q (Figure 1-2). 
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( )
( )
11 12 13 12 13 12 13
21 22 23 21 21 23 23
31 32 33 31 32 31 32
1 2 3 1 2 3
1 1
2 2
3 3 (
q q q q q q q
q q q q q q q
q q q q q q q
     − +  = ≈   − +   − +    
Q
)
  
Figure 1-2 Transition intensity (rate) matrix for a time-homogenous 3-state Markov 
model.  
 
The rate of staying in state i, is constrained to equal the rate of leaving i 
(Norris, 1997). This is imposed by the fundamental property of the Markov process 
that dictates that flow in and out of the state must be equal. The exception is when the 
state is absorbing such that the flow out of the state is zero. In this case 1 is imposed 
on the diagonal (Norris, 1997).   
The probability of transition in a Markov process depends on the transition rate 
and the observation interval. The transition probabilities can be estimated from the 
transition rates.  Consider the time-homogenous model where the transition rates are 
constant. The distribution of time between transitions follows a one-parameter 
exponential distribution; in fact, the exponential distribution is the only distribution 
that has the memory-less feature (Meerschaert, 1999b).  The cumulative density 
function of time is  where λi is the rate of transition up to time t 
(Meeker and Escobar, 1998a, Meeker and Escobar, 1998b). The cumulative 
distribution function describes the probability of transition before time t and thus can 
be used to derive the probability of transition from the rate of transition such that 
where t is the time period for which the probability is estimated (Beck and 
Pauker, 1983, Miller and Homan, 1994). 
( ) 1 itiF t e
λ−= −
1 itp e λ−= −
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In matrix notation, ( ) ( )d t dt t=P P
( ) ( , )t s s= +
Q
t
. Since the process is stationary in the 
time homogeneous model, P P (Kalbfleisch 
and Lawless, 1985, Qin, et al., 1997). The calculation of the individual transition 
probabilities for any given value of t requires the spectral decomposition of Q(t) 
(Marshall, 1990, Norris, 1997). 
(0, ) and ( ) exp( )t t t= =P P Q  
1.5 Time Non-homogeneous Markov Process  
Both discrete time and continuous time Markov processes may be time non-
homogeneous. The relationship between the transition rates and probabilities are more 
complex and computing probabilities is difficult (Marshall, 1990). In a time non-
homogenous Markov process, the transition rate and the transition probability depend 
on the time of observation of the process. Similar to time homogeneous Markov 
processes, the transition probability depends on the observation interval but the 
transition rate does not. Because of their complexity, time non-homogeneous Markov 
process will not be addressed further in this work (Marshall, 1990). 
1.6 Markovian Assumption 
The Markovian assumption initially appears restrictive but is easily met in 
most cases. Adding states to the model may be useful when situations possibly violate 
the Markovian assumption (Hillis, et al., 1986, Sonnenberg and Beck, 1993, de Kruyk, 
et al., 1998).  For example, passage to the state of death may occur at a different rate 
following first remission of a disease than second remission. Under the strategy of 
adding states, entry into the first of these states forces movement into the following 
state and there is no backward movement. These states are referred to as tunnel states 
since they can only be visited in a fixed sequence (Sonnenberg and Beck, 1993).   
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Although addition of states may avoid violation of the Markovian assumption, 
it will increase the complexity of the model and reduce the density of the data for 
estimation of transition probabilities.  At some point in model construction, there may 
be limited gain from adding states in the face of loss of precision of estimation of the 
transition probabilities.   
1.7 Time Homogeneity and Models with Covariates  
The assumption of time homogeneity simplifies the Markov model and is often 
a convenient baseline for analysis (Kalbfleisch and Lawless, 1985). Insight can be 
obtained by examination of departures from this model.  Consideration of the 
assumption of time homogeneity is however, warranted. Many covariates may be 
responsible for causing the process to be non-homogenous over time.  The most 
common covariate in people is age.  Time homogeneity is often violated in modeling 
chronic disease in people since aging and development of concurrent illnesses have a 
significant influence on mortality rate (Beck, et al., 1982). Whether aging significantly 
influences mortality in veterinary studies is undetermined. 
A strategy for accommodating non-homogenous transitions is to add states to 
the model. The strategy comes at the cost of increased model complexity and 
subsequent computations (de Kruyk, et al., 1998).  Alternately, separate matrices using 
the same model can be created and compared for different time periods (Urakabe, et 
al., 1975, Sendi, et al., 1999b). For example, where age-dependent transition was 
suspected, investigators stratified the model by age groups and created separate 
transition matrices for different age groups (Schaubel, et al., 1998, Jacobs, et al., 2001, 
Pokorski, 2001).  The strategy of creating separate matrices can also be used to 
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compared fixed covariates such as treatment and disease characteristics (Silverstein, et 
al., 1988, Sendi, et al., 1999a, Jacobs, et al., 2001).  
For some causes of time-dependent transitions, separate models may be 
required for each time interval that run simultaneously (Kalbfleisch and Lawless, 
1985).  In Schaubel’s study on the progression of renal disease, transition was 
dependent on age and whether or not the subjects had diabetes.  Separate models were 
created for age groups with or without diabetes (Schaubel, et al., 1998). In this case, 
the models were separate and no information was transferred between models. In de 
Kruyk’s study on aortic valve replacement, transitions were dependent on the time 
since the previous valve replacement and the number of previous replacements (de 
Kruyk, et al., 1998).  The latter dependency possibly represents a Markovian 
assumption violation. Separate models were created for different valve replacement 
occurrences. The models were run simultaneous and there was some information 
transfer between models.  In Ward’s study on the effects of climatic variables on 
Bluetongue virus infection in Australian cattle herds, two separate models were used 
and the matrices were multiplied to determine the overall matrix of the model (Ward 
and Carter, 1996a). The first matrix represented the risk of infection in various age 
groups while the second matrix represented the transition of cattle from one age-
specific class to the next.   These matrices, multiplied by a distribution vector, 
determined the distribution vector of the proportion of cattle infected with bluetongue 
in each age class.  
Another option for incorporating time-dependent covariates in the Markov 
process is to build the covariates into the determination of the time-dependent 
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transitions rates (Kay, 1986, Marshall, 1990, Wanek, et al., 1994, Marshall and Jones, 
1995, Christodoulou and Taylor, 2001, Jacobs, et al., 2001). The transition rate 
at time t, is described by where is the baseline 
transition rate from state i to j at time t, β is the vector of regression coefficients 
and is the vector of covariates constant for every t within [ ]  
(Kay, 1986, Marshall, 1990). This technique is akin to regression on the hazard 
function estimation (Marshall, 1990, Perez-Ocon, et al., 2001).  Fixed covariates can 
also be built into the determination of transition rates for the time-homogenous 
process, assuming a constant baseline transition rate such that  where λij is 
the baseline transition rate from state i to j, β is the vector of regression coefficients 
and is the vector of covariates (Marshall, 1990).  Using the technique of regression, 
many covariates can be incorporated such as population mortality (Beck, et al., 1982, 
Beck and Pauker, 1983, Kuo, et al., 1999, Jacobs, et al., 2001), disease characteristics 
(Marshall, et al., 1993, Wanek, et al., 1994), age (Christodoulou and Taylor, 2001) and 
treatment (Perez-Ocon, et al., 2001). 
( , ( )ij t tλ z
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lz
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1.8 Description of Disease  
An attractive feature of Markov models is their ability to describe the course of 
disease over time.  This is especially attractive for modeling chronic disease since a 
subject’s state of health during the course of disease influences medical decisions. The 
transition probability matrix P summarizes the probabilities of events and can be used 
to depict the probabilistic course of the disease for a population or for an individual 
with a known health state.   
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Matrix multiplication estimates the probability of reaching a certain state for an 
average subject after n cycles. In addition, matrix multiplication estimates the 
proportion of a population that reside in a certain state after n cycles. The elements of 
the probability matrix pij describe the probability of going from state i to state j in one 
cycle.  The operation  (n times), depicted as  yields a matrix 
denoted the nth matrix, whose individual elements pij(n) are the probabilities of 
transition to state  from state i after n cycles (Stewart, 1994). This information is 
pertinent to a population as a whole rather than the individual.  
⋅ ⋅ ⋅ ⋅ ⋅P P P P ( )nP n= P
P
j
A transient analysis is used to predict future health states for an individual 
subject, conditional on their current health state (Jain, 1986).  Consider the probability 
of being in any one of a comprehensive and mutually exclusive assembly of  m states 
at a given time t, denoted by the vector  where 
is the probability of being in health state i at time t. The probability of moving 
from state i  to j  is given by the ijth element of the P matrix, thus the probability of 
being in state j at time t is given by the jth element of the vector  such that 
.  Iteration for further time sequences generates a series of 
probabilities over many cycles (Urakabe, et al., 1975, Beck and Pauker, 1983, 
Silverstein, et al., 1988, Bauerle, et al., 2000).  The transient analysis provides 
prognostic information suitable for individual decision-making (Urakabe, et al., 1975, 
Silverstein, et al., 1988). Graphic depiction of these transient probabilities produces a 
probability curve, which is illuminating (Urakabe, et al., 1975, Silverstein, et al., 1988, 
de Kruyk, 1998 #149, Kuo, et al., 1999, Bauerle, et al., 2000, Myers, et al., 2000). The 
[ ]0 1 2 1( ) ( ) ( ) ( ) ( )mt p t p t p t p t−= ⋅⋅⋅p        
( 1)t +p
( )ip t
( 1p ) ( )t t+ = ⋅p
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probability curve is sometimes referred to as a “Markov survival curve”, in the case of 
a model with absorbing states (Sendi, et al., 1999b). 
Transient analysis may cause convergence of the probability distribution vector 
to tend to a limiting specific value as n increases.  That is, as the number of cycles, n, 
increases, the probability vector approaches a limiting value. This is the concept of 
steady state.  Not every Markov chain possesses a steady state. The steady state vector 
can be solved using the equation   where  is the steady state vector for m 
states that contains the steady state probabilities  under the constraint 
that  (Meerschaert, 1999b). When a model contains absorbing states that 
communicate directly or indirectly with all transient states, the state distribution vector 
will converge so that the probability of being in a transient state as zero. 
⋅π = π P π
,π π0 1 2 -, ,.... mπ π 1
1iπ =∑
1.9 Model Validation  
The two most fundamental assumptions commonly underlying a Markov 
model are the Markovian assumption and time homogeneity (Garg, et al., 1990, 
Marshall, et al., 1993, Hendriks, et al., 1996, Sendi, et al., 1999a).  Assessing the 
model to determine if these assumptions hold may take several forms.   
At its simplest, the hypothesis of time homogeneity for a discrete Markov 
chain is tested by the likelihood ratio test (Jain, 1986). This test compares the observed 
transition probabilities with expected probabilities derived from the model 
(Kalbfleisch and Lawless, 1985).  
Data splitting (Lawless and Yan, 1993, Schaubel, et al., 1998) and sensitivity 
analysis can be used to critique the model (Lawless and Yan, 1993, Cowen, et al., 
1994, Sendi, et al., 1999b, Aoki, et al., 2000, Jacobs, et al., 2001). These methods do 
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not specifically test the assumptions but reveal inconsistencies in the model.  
Inconsistencies may reflect violation of assumptions or other problems such as 
imprecise estimates or flawed data.   
Data splitting is separating the data set and using one portion to fit the model.  
The model is used to predict the expected state distribution for a future time period 
that are compared to the observed state distribution of the remaining data already 
collected (Lawless and Yan, 1993, Schaubel, et al., 1998).  If the data is dense enough, 
separate models may be fitted for several different time intervals and compared 
(Kalbfleisch and Lawless, 1985). This provides a method of internal validation of the 
model (Schaubel, et al., 1998, Sendi, et al., 1999b). 
Sensitivity analysis provides a tool for studying the behavior of the model 
(Sendi, et al., 1999b, Aoki, et al., 2000). It does not provide any confidence statements 
about the results.  One-way sensitivity analysis provides an incomplete estimation of 
uncertainly because the results are a function of the entire matrix and not just a single 
probability. Assessing overall uncertainty should be done by statistical approaches 
such as bootstrapping or Bayesian methods (Carpenter, 1988, Craig, et al., 1999, Craig 
and Sendi, 2001). 
Sensitivity analysis puts the probability of variables in the model through a 
range of possible (plausible) values (0 to 1) and the outcome of the model is 
examined.  Traditional one-way sensitivity analysis examines one variable at a time 
(Aoki, et al., 2000).  Manipulation of two or more variables together becomes complex 
because a two or more dimensional polyhedron rather than a single line describes the 
range of values (Jensen and Bard, 2002b).  
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The predictive validity of a model can be tested by comparing predicted 
intermediate or final outcomes with observed outcomes of a separately cohort (Sendi, 
et al., 1999b).  An independent data source suitable for comparison may be difficult to 
find and data splitting can be used as an alternative measure (Lawless and Yan, 1993, 
Schaubel, et al., 1998, Sendi, et al., 1999b).   
Face validity defined by Sendi describes how closely what happens in the 
model compares to what should be happening, using different starting conditions and 
medical interventions (Sendi, et al., 1999b).  Sensitivity analysis provides some 
insight into face validity of a model. However, additional scrutiny by visual inspection 
is helpful.  Comparison of the “Markov survival curves” generated by transient 
analysis from sensitivity analysis reveal if changes to the model give unexpected 
results.   
1.10 Linking Markov Models to Survival Analysis  
Although the Markov model is presented here as an alternate for survival 
analysis, the methodologies used for survival analysis and Markov models can be 
linked.  
The Kaplan-Meier product limit model (of survival analysis) is a simple 
stochastic process that is defined by a set of transition matrices (one for each follow-
up time interval) that contain probabilities of transition from state ALIVE to state 
DEAD (Hillis, et al., 1986). The transition matrix over the cycle t to t+1 has the 
following form (Figure 1-3). This would reduce to P for the time homogenous model, 
which would be assumed in the Kaplan-Meier analogy. 
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Figure 1-3 Probability matrix for a two-state Markov model of survival.  
 
Thus, pt, t+1 is the probability of staying alive over the cycle t to t+1. If the 
Markov process is applied to derive the estimated probabilities of moving from 
ALIVE to DEAD at each time period, this calculation would equal the Kaplan-Meier 
product limit estimate of the survival function, given 100% complete observations 
(Hillis, et al., 1986, Marshall, 1990). 
The corresponding transition rate matrix has the following form where the rate 
of dying over the cycle t to t+1 is described as (Figure 1-4). Again, this would 
reduce to Q for the time-homogenous model.  
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Figure 1-4 Transition intensity matrix for a two-state Markov model of survival.  
 
The probability transition matrix is derived by spectral decomposition of Q, 
remembering the exponential distribution of time (Figure 1-5) (Marshall, 1990).  
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Figure 1-5 Spectral decomposition of the probability transition matrix Q.  
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Thus, the probability of being alive at time t is .  This is equivalent to 
the exponential survival function (Hillis, et al., 1986, Marshall, 1990). 
t
tp e
λ−=
( ) tS t e λ−=
1.11 Censoring and Multiple Outcomes  
A proportion of subjects in a clinical study are sometimes removed or lost from 
the study before the outcome of interest is recorded.  There are many reasons for this 
including completion of the study, patient or owner decisions to remove themselves 
from the study, development of other problems that prohibit completion of the study 
and death due to other causes. These observations are considered right-censored 
observations (Lagakos, 1979).  
A powerful feature of survival analysis is the ability to use information from 
right-censored observations. The underlying assumption for using these observations 
to estimate parameters is that the censored observations are not informative. That is, 
they do not provide any information regarding the time at which the outcome of 
interest occurs.  If the observations are clearly noninformative, then standard survival 
analysis methods can be employed (Lagakos, 1979). It is not always apparent that 
censoring is noninformative however, it is often clear that censoring is related to the 
ultimate survival time.   The most common forms of informative censoring are 1) 
where subjects (or owners of pets) remove themselves from the study for reasons 
possibly related to treatment; 2) where subjects experience a specific critical event 
such as metastasis that prohibits them from continuing in the study; and 3) where the 
subjects fail due to a secondary outcome of interest that causes them to be censored 
according to the primary outcome of interest (Lagakos, 1979). This third scenario also 
represents the presence of a competing risk. It is often easiest to view competing risks 
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as a censoring problem. The third scenario becomes complicated because the objective 
for most competing risks is to estimate the time of failure from a particular cause when 
other causes of failure are not in effect.  However, in this case, the complete 
observation of the survival time of interest is an unachievable event (Lagakos, 1979). 
Euthanasia fits this scenario.   
Censoring can be accommodated in Markov models under the same 
assumption of noninformation (Hillis, et al., 1986, Marshall, 1990). Subjects only 
contribute to the risk set for as long as they are observed and do not contribute to 
calculations of transition from state they are in when they are censored (Olschewski 
and Schumacher, 1990, Marshall and Jones, 1995). In a simple two-state model, right-
censoring can be linked to conventional survival analysis as before.  Using the 
exponential survival function, the contribution of a censored observation is the 
survival function (Lee, 1992b). Similarly, for the time homogenous two-
state Markov model, the contribution of a right-censored observation is equivalent to 
still being in the ALIVE state at the end of the study and therefore the contribution 
over cycle t to t+1 is (Figure 1-5).   
( ) tS t e λ−=
, 1t tp + = te λ−
The use of a Markov model for right-censored data has an advantage over 
survival analysis in that each censored subject contributes more information to the 
model than it can contribute to survival analysis with one end point (that the subject 
did not reach). The prior state transitions these subjects experience add useful 
information (Hillis, et al., 1986). 
Creation of separate absorbing states may be indicated when there is 
informative censoring or competing risks (Hillis, et al., 1986, Diggle and Kenward, 
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1994).  Markov models allow joint analysis of competing risks by including several 
absorbing states (Chevret, et al., 2000).  The Markov model is particularly suited for 
the scenario where subjects are removed from the study because they develop a critical 
event that precludes them from developing the outcome of interest, for example 
metastasis (Lagakos, 1979). The Markov model can integrate this information into the 
description of the disease.  Also, including the subject avoids loss of information on 
prior transitions.   
Survival analysis becomes unreliable when a large proportion of the data is 
censored, since the estimates for the tail of the survival function are based on fewer 
and fewer subjects (Hillis, et al., 1986, Lee, 1992a). Intuitively, this would also affect 
estimation from the Markov model since transition probabilities to absorption states in 
latter cycles would be based on few observations.  The effect of ignoring informative 
censoring in survival analysis and Markov models is biased estimation (Hillis, et al., 
1986). For the exponential survival function, the effect is to underestimate the hazard 
and overestimate the median survival time (Lagakos, 1979). Ignoring informative 
censoring in Markov models would intuitively effect estimation in the same way since 
absorption probabilities would be underestimated.   
Although not a focus of this investigation, Markov modeling is valid with left 
censoring (Hillis, et al., 1986, Commenges, 1999).  Left censoring, where subjects 
enter the study at unknown stages of disease, is rarely documented in veterinary 
clinical studies although it is quite common. Subjects enter a cohort at various stages 
of a disease, rather than in the pre-diseased state or a specific state of disease. The first 
observations from some subjects occur in early disease while first observations from 
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others occur in more advanced stages of disease. Health states that account for 
different disease stages can be incorporated into a Markov model and subjects can 
enter the study in the appropriate health state (Commenges, 1999). 
1.12 Estimation of Expected Survival  
The duration of expected survival or life expectancy is common measure of 
success for clinical studies and is the basis for clinical decision-making.  Life 
expectancy is defined as the average future lifetime of a cohort of subjects with 
identical clinical features (Beck and Pauker, 1983).   The Markov model can be used 
to estimate life expectancy.   For consistency and to use terminology more familiar to 
veterinarians, the term “expected survival” is used. This term helps to convey that the 
estimates are projected survival time. It is intuitive for any Markov process with at 
least one absorbing state that can be reached from any transient state, that the 
probability of eventual absorption is one (Beck, et al., 1982, Beck and Pauker, 1983, 
Briggs and Sculpher, 1998, Bauerle, et al., 2000).   For example, if the absorbing state 
is death, eventually every subject dies. The sum of the expected duration time spent in 
transient states before absorption modeled by the Markov process is the expected 
survival of a cohort of subjects (Beck and Pauker, 1983, Briggs and Sculpher, 1998).   
Expected survival estimated by Markov model analysis should be thought of as 
an extrapolated survival under the assumption that the constant transition probabilities 
continue to apply in the future (Silverstein, et al., 1988). Thus, expected survival is an 
estimate based on the probability information obtained from an observed cohort. This 
is in contrast to estimated median survival time derived from a survival function, 
which is a summary of the survival times recorded for a cohort.  Most veterinary 
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clinical studies report median survival times estimated from Kaplan-Meier survival 
function as a summary measurement for diseases and treatment outcomes. 
Investigators often misinterpret this as expected survival for an individual, and 
prognosis and selection of treatment for an individual is often based on this 
measurement (Berg, et al., 1992, Blackwood and Dobson, 1996, Davidson, et al., 
1997, Crawshaw, et al., 1998, Dunning, et al., 1998, Khanna, et al., 1998). 
Durations spent in transient states and expected survival can be estimated from 
Markov models using matrix solution, cohort simulation and Monte Carlo simulation.  
1.12.1 Fundamental Matrix Solution  
Matrix solution provides an exact solution of the time spent in each state, 
conditional on the entry state in which an individual enters the model. Matrix solution 
is restricted to time homogeneous Markov chains. The transition probability matrix of 
a chain that contains absorbing states is divided into four sections: Q contains 
transition probabilities between transient states; R contains transition probabilities 
from transient to absorbing states; O is a zero matrix, and I is an identity matrix 
(Figure 1-6) (Beck and Pauker, 1983, Brown and Brown, 1990a).   
  To: 
  Transient  
States 
Absorbing  
States 
Transient 
States 
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Absorbing  
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Figure 1-6 Separation of a probability transition matrix containing absorbing states 
into 4 components --  Q contains transition probabilities between transient states; R 
contains transition probabilities from transient to absorbing states; O is a zero matrix, 
and I is an identity matrix.  
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The average number of cycles that a subject resides in transient states before 
absorption, given a specified starting state, is estimated from the fundamental (N) 
matrix. Calculating N is the matrix algebraic equivalent of taking the inverse of the 
transition probabilities in Q (Beck and Pauker, 1983, Brown and Brown, 1990b). The 
N matrix specifies the average number of cycles that a subject resides in transient 
states such that N I  where I is a identity matrix and Q is the square matrix of 
the transient probabilities within P (Appendix I) (Beck and Pauker, 1983, Brown and 
Brown, 1990b). Multiplication of the number of cycles by the length of the cycle gives 
the expected duration in each state, conditional on a starting state.  The sum of these 
durations gives an estimate of expected survival, conditional on a starting state (Beck 
and Pauker, 1983).  
-1( - )= Q
The variance of N is given by the V matrix with where  
is a copy of N with only the diagonal entries preserved (and zeroes elsewhere) and  
is a matrix with each entry of N squared (Appendix II) (Beck and Pauker, 1983, 
Silverstein, et al., 1988). Each element of V represents the variance of the 
corresponding element of N. The square root of each element of V is the standard 
deviation of the corresponding element of N. 
2(2 )′= − −V N N I N ′N
2N
1.12.2 Markov Cohort Simulation  
Cohort simulation uses a hypothetical cohort, for example 10,000 subjects, to 
illustrate the predicted experience of subjects (Beck and Pauker, 1983, Sonnenberg 
and Beck, 1993, Briggs and Sculpher, 1998, de Kruyk, et al., 1998, Bauerle, et al., 
2000). The entire cohort begins the model at time 0 in the initial disease state. If 
necessary, the cohort can be distributed through several initial states. At each cycle, a 
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vector of the distribution of the subjects among the states of the model is multiplied by 
the transition probability matrix P and the adjusted vector of the distribution of the 
subjects among the states of the model after one cycle is obtained. This is akin to 
performing a transient analysis. Iterating the analysis for many cycles builds a profile 
of the number of subjects expected in each state of the model over time. The process is 
continued until there are no (or a restricted number) of subjects in the transient states.  
The sum of subjects in each state over all simulation cycles is divided by the number 
of subjects originally in the cohort to derive the mean number of cycles spent in each 
state. The mean number of cycles, multiplied by the cycle length, estimates the mean 
duration spent in each state, conditional on the starting state (Beck and Pauker, 1983, 
Sonnenberg and Beck, 1993, Briggs and Sculpher, 1998). Again, the sum of the 
durations spent in transient states is an estimate of the expected survival, conditional 
on the starting state.  
Cohort simulation enables a number of useful features. During the course of 
analysis, adjustments for changes in the utility of the states can be made. This is useful 
in cost-effectiveness studies (Briggs and Sculpher, 1998), but also in quality-of-life 
studies where certain health states have different value to a subject than others (Gore, 
1988). It is also possible to incorporate time-dependent probabilities and include half-
cycle correction for long cycles (Beck and Pauker, 1983, Sonnenberg and Beck, 1993, 
Briggs and Sculpher, 1998). Cohort simulation will not provide information on the 
distribution or variance of the estimates (Beck and Pauker, 1983). 
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1.12.3 Monte Carlo Simulation  
Monte Carlo simulation passes hypothetical subjects through the Markov 
process one by one. Monte Carlo simulation uses a random-number generator to 
assign a value to each of the random variables (states) in accordance with its 
probability distribution (transition probabilities) (Briggs and Sculpher, 1998, 
Meerschaert, 1999a).  Thus, the path of each subject will differ according to random 
variation and repeated simulations can be considered independent random trials  
(Meerschaert, 1999a).  The subject is followed through the process until absorption.  
The number of cycles until absorption allows estimation of the duration spent in each 
of the health states and expected survival (Beck and Pauker, 1983). Monte Carlo 
simulation is time consuming but allows considerable flexibility. Subjects can start in 
different health states, varying utilities can be applied and time-dependent 
probabilities can be incorporated. The variance of estimates is close-formed and easy 
to calculate.  Increasing the number of simulations will reduce the variance of the 
estimates (Beck and Pauker, 1983, Briggs and Sculpher, 1998, Meerschaert, 1999a).  
1.13 Interpretation of Estimates 
Estimates of state durations and expected survival derived from matrix 
solution, cohort simulation and Monte Carlo simulation give similar results if 
equivalent transition probabilities and distributions are used, and if a large number of 
life histories are generated with the Monte Carlo approach (de Kruyk, et al., 1998). 
The variance of these estimates may vary. Cohort simulation is restrictive and cannot 
generate a variance estimate.  Monte Carlo simulation has the advantage of generating 
variances very easily, which can be reduced by increasing the number of simulations.  
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Matrix solution invariably generates large variance estimates, of the magnitude of the 
estimated state durations (Silverstein, et al., 1988, Briggs and Sculpher, 1998).  The 
variances are analogous to the variance of a proportion. Although the probabilities 
used in a Markov model may be calculated from a large sample with many subject-
time interval observations, precision is lost when the incidence rate is used to 
approximate the probability of transition. Incidence rate approximation to the 
transition probability can be used when the transition rate is small or the time interval 
is short. However, for precision, the exact probability calculated from the incidence 
rate should be used according to the formula where  is the rate and t is 
the time interval (Silverstein, et al., 1988). Estimates of expected survival are most 
influenced by imprecision when the probability estimates are small since survival is 
the inverse of the probability or rate.  
1 itp e λ−= − iλ
Probability estimates used to construct models and estimates subsequently 
derived from the model may include errors. Any model is only as good as the quality 
of data used to build it (Beck, 1988).  The precision of estimated probabilities depends 
on the number of transitions and the duration of observations used to calculate the 
probabilities. Imprecise estimates based on small numbers of transitions will have a 
large effect on the estimates of state durations and expected survival (Silverstein, et 
al., 1988). The problem of small numbers of transitions may be resolved by combining 
states, if this does not violate the Markovian assumption (Silverstein, et al., 1988). 
For the discrete Markov chain, the length of each cycle can overestimate or 
underestimate state durations. Long cycles (years) have the most effect. The Markov 
model assumes that the transitions occur between cycles and that subject membership 
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of each state of the model is constant over the duration of each cycle. In reality, 
subjects move between different states continuously. A half-cycle correction can be 
used to avoid assumption that subjects move between states at the beginning or end of 
a cycle (Sonnenberg and Beck, 1993, Briggs and Sculpher, 1998, Bauerle, et al., 
2000).  This is equivalent to assuming that, on average, subjects move between states 
in the middle of a cycle.  
In a clinical study, it is unlikely that observations are always made at restricted 
intervals.  Transitions may be missed or erroneously assumed to occur at the time of 
observation.  Methods to accommodate these problems are mathematically intense but 
the Markov model can be extended to situations where the observations are made at 
regular time intervals, at irregular time intervals, or even to situations where the 
observations are made at irregular intervals but the exact time of transition during that 
interval is unknown (Marshall, 1990, Andersen, et al., 1991, Lawless and Yan, 1993, 
Lee and Kim, 1998, Craig, et al., 1999). Because of their complexity, these 
applications will not be addressed further.  
1.14 Application in Veterinary Medicine 
Various applications of Markov models have been reported in the veterinary 
literature, primarily in large-animal population medicine.  To date, there are no reports 
of Markov models used to evaluate time-event data, or in particular, survival data,  
from clinical studies in large or small animals.  
Selected examples of the veterinary reports include the work of Oltenacu and 
Natzke. In 1975,  Oltenacu and Natzke used a Markov chain model to describe the 
progression of mastitis in dairy cows (Oltenacu and Natzke, 1975). The model 
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described seven infection states examined at monthly intervals.  Simulation and cost-
effective analysis was used to examine the effect of mastitis on milk productivity.   
In 1988, Carpenter described a microcomputer program that could be used to 
model disease using Markov chains (Carpenter, 1988). Carpenter commented 
commented on four studies that had been published after that of Oltenacua and 
Natzke, which used Markov chains to describe disease processes in production 
animals (Schwabbe, et al., 1977, Carpenter and Riemann, 1980, Lehenbauer and 
Harmann, 1982, Zessin and Carpenter, 1985). 
Ward and Carpenter published a series of reports describing construction of a 
state transition model of the climatic factors and herd immunity affecting bluetongue 
virus infection in Australian cattle (Ward and Carter, 1996a, Ward and Carter, 1996b, 
Ward and Carpenter, 1997). The model used in these studies included sequential 
matrices, the first representing the risk of infection in 10 age groups of cattle and the 
second matrix represented transition between age groups  and reproductive 
performance. Climatic factors were regressed on the herd incidence to establish the 
transition probabilities. Model validation was performed by comparing estimates to a 
different observed cohort, and by sensitivity analysis (Ward and Carter, 1996a, Ward 
and Carter, 1996b, Ward and Carpenter, 1997). 
In 1988, Vonk Noordegraaf et al used a Markov chain to evaluate the spread 
and control of infectious bovine rhinotracheitis in the Netherlands (Vonk Noordegraaf, 
et al., 1998). A two-state model of non-infectious to infections was used to evaluate 
the effect of vaccination strategies through a sensitivity analysis for 5 speculated 
vaccination regimes. Cost analysis was also performed.  
 28 
More recently, Schlosser and Ebel (Schlosser and Ebel, 2001) used a Markov 
chain and Monte Carlo simulation to estimate present disease prevalence from 
historical data. This model was applicable to risk assessment in trade, food safety and 
domestic animal-health regulations. 
The only clinical application of Markov methods was the construction of 
decision trees for estimating the value of removing an undescended testicle from a 
young dog (Bosch, et al., 1989, Peters and van Sluijs, 2002).  These investigations 
used decision trees to determine the most valuable treatment.  Interestingly, utilities 
for the outcomes were based on life expectancy of dogs with various conditions. The 
probability-adjusted utility of treatment options was consequently measured in years 
of life expectancy (Peters and van Sluijs, 2002).  This did not represent survival 
estimation since the utilities were arbitrarily assigned, based on prior knowledge from 
the literature.  
1.15 Summary and Objectives for Present Studies 
The Markov model is appealing for analysis of time-event data in veterinary 
clinical studies for several reasons.  Firstly, Markov models can describe the course of 
disease as a series of probable transitions through several health or disease states.  This 
is an advantage over the restricted, two-state description of survival analysis. A 
Markov model can accommodate informative censoring and competing risks by 
addition of absorbing states. This offers a method to examine absorption by 
euthanasia. Markov models allow estimation of expected survival based on the hazard, 
that is, based on the future probability of dying, conditional on survival to the present.  
This is a more clinically relevant measurement and easier for the veterinarian and 
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owner to interpret.  The graphic depiction of transient probabilities over time allows 
an integrated view of the disease course and provides information for individual 
decision-making. Assumptions of the Markovian property is required, but if 
restrictive, can be met by addition of states to the model.  
The work encompassed in this dissertation evolved from the dissatisfaction 
with the current methods used to evaluate time-event data, in particular survival data,  
in veterinary clinical studies.  Almost all studies restrict analysis to Kaplan-Meier 
estimation.  Studies often violate underlying assumptions required for analysis, results 
are seriously misinterpreted, and issues such as left-censoring are ignored.  All 
investigators choose to ignore the issue of observations from euthanized subjects.  
Unfortunately, life-determining decisions are continually made based on the results 
and interpretation of such studies and many veterinarians (and then owners), who are 
not proficient epidemiologists or statisticians, are mislead.   
The objectives of the studies presented in this dissertation were the following: 
Study 1 – To illustrate how classification protocols for observations from 
animals euthanized and dying will substantially influence the survival estimates using 
Kaplan-Meier product limit estimation. 
This study was important to highlight the inadequacy of using only Kaplan-
Meier product limit estimation to evaluate veterinary clinical studies. Results of this 
study showed that Kaplan-Meier product limit estimation of the survival function is 
sensitive to classification protocols, particularly in the presence of a high frequency of 
right-censored observations.  It is clear that Kaplan-Meier estimation cannot be used 
when there is informative censoring and hence is inadequate for accommodating 
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observations from euthanized animals.  In addition, it is clear that Kaplan-Meier 
estimation does not provide information useful for individual decision-making or 
prognostication.  This is however, information that the veterinarian and client demand.  
In the search for an alternate to Kaplan-Meier estimation, the application of Markov 
modeling to describe disease was discerned as an appealing methodology.   
The objectives of the second study followed naturally:   
Study 2 - To describe the course of a chronic disease (canine lymphoma) using 
a time-homogenous Markov chain.  The Markov model would accommodate left 
censoring through entry into different transient states, and informative right censoring 
by inclusion of additional absorbing states. Estimates of expected survival would be 
attained by matrix inversion or Monte Carlo simulation and would be compared to 
estimates using Kaplan-Meier product limit methods. 
The second study was important to explore the feasibility of using a simple 
Markov model for a typical veterinary clinical data set. Results of the second study 
showed that this methodology could be applied and achieve plausible results.  Since 
this data set was relatively small (although quite large compared to most veterinary 
clinical studies), the intent was to explore the methodology and not the disease.  Thus, 
the third study was performed using a larger data set with the intent to say something 
about the disease under investigation.  In addition, different techniques in estimation 
of transition probabilities, and in analysis of the data were used to gain familiarization 
with techniques other than those used in the second study.  The specific objectives of 
the third study were: 
 31 
Study 3 – To construct a Markov model of the course of vaccine-associated 
sarcoma in cats. The course of disease, predicted by the transition probability matrices, 
would be compared for cats treated with different protocols.  Estimates of expected 
survival derived from Monte Carlo simulation would be compared and interpreted in 
light of individual decision-making and treatment selection.  
The third study was required so that the methodology could be applied to a 
data set in a critical manner and information useful for individual decision making 
could be derived. The study did provide relevant results and described the course of 
the disease in an integrated way that has not been achieved by prior studies on that 
particular disease.   
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2.1 Introduction 
Survival time can be broadly defined as the time to the occurrence of a given 
event.  This event can be the development of a disease, response to a treatment, time to 
relapse of disease, or (more traditionally) death (Lee, 1992a).  Investigators often apply 
survival analysis to clinical data to evaluate such event-times and also to determine if 
there is a difference between these event-times for subjects grouped by different 
characteristics.   
The issue of euthanasia is unique to veterinary studies evaluating survival time.  
The decision to euthanize an animal is based on several factors that include the health of 
the animal, as well as factors such as age of the animal and cost of the treatment (Gobar, 
et al., 1998, Mallery, et al., 1999). 
Recent veterinary studies evaluating survival data have over 50% of  the total 
observations taken from euthanized animals (Cox, et al., 1991, Berg, et al., 1992, Munana 
and Luttgen, 1998, Zwahlen, et al., 1998).  The methods described to account for 
observations from euthanized animals in these studies vary.  Some investigators deleted 
the observations (White, 1991). Some studies also deleted observations from animals lost-
to-follow-up (Johnson, et al., 1989). Most investigators equated the euthanized animals 
with animals that died from the disease of interest during the study period (Prymak, et al., 
1988, Cox, et al., 1991, Schwarz, et al., 1991b, Schwarz, et al., 1991a, Berg, et al., 1992, 
Spodnick, et al., 1992, Reeves, et al., 1993, Hammer, et al., 1995, Dunning, et al., 1998).  
Other investigators gave no indication of the number of observations that came from 
euthanized animals (McNiel, et al., 1997, Erhart, et al., 1998, Khanna, et al., 1998, 
Lucroy and Madewell, 1999).  Many investigators did not report how the observations 
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from euthanized animals were specifically evaluated (Thompson and Fugent, 1992, 
Straw, et al., 1996, Kuntz, et al., 1997, Munana and Luttgen, 1998, Wood, et al., 1998, 
Zwahlen, et al., 1998) -- yet presented estimates of the median survival time and used this 
information as the focus of the manuscript.   
Although apparently more straight-forward, the issue of how to account for 
observations from animals that die from causes other than the disease of interest is also 
inconsistent.  Because these animals do not die from the disease of interest, observations 
from these animals should be right-censored – a right-censored or incomplete observation  
is one from an animal that did not reach the outcome of interest during the study period 
(Lee, 1992a). Some investigators determine death as the endpoint -- regardless of cause 
(Khanna, et al., 1998). Intuitively, evaluating all observations as complete (that is, an 
observation from an animal that did reach the outcome of interest during the study period)  
-- regardless of the cause of death -- will result in erroneous inferences from the data.  
Some investigators tried to address incomplete observations by right-censoring 
observations from animals that were euthanized or died because of problems unrelated to 
the disease of interest (Kosovosky, et al., 1991, Wallace, et al., 1992, Blackwood and 
Dobson, 1996, Straw, et al., 1996, McNiel, et al., 1997, Dunning, et al., 1998). However, 
these investigators still included observations from animals euthanized because of 
problems related to the disease of interest as complete observations in the estimation of 
median survival time.  Also, observations from animals for which the cause of death or 
euthanasia was unknown were included as complete observations --  possibly an attempt 
to be conservative (Schwarz, et al., 1991a, Schwarz, et al., 1991b).  Although the methods 
used in these cited studies address incomplete observations, they still fail to resolve the 
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issue that euthanasia is not an endpoint solely determined by disease pathology.  Equating 
observations from euthanized animals to complete observations from animals that died 
from the disease of interest is inaccurate and will result in biased estimates of the survival 
function and median survival time.   
Two major issues are apparent: 1) there is bias in the estimation of survival time;  
hence there should be lack of confidence in the inference from any  survival analysis 
when observations from euthanized animals are considered complete; and 2) because the 
methods for evaluating the observations from euthanized animals (and animals that died 
or were lost-to-follow-up) are inconsistent, the comparison of results between studies is 
impossible.  The objective of our study was to illustrate the effects of alternative-
classification protocols  (for observations from euthanized animals and animals that died 
of causes other than the disease of interest) on the estimate of the survival function and 
median survival time.      
2.2 Methods 
For the purpose of this paper, the terminology “event-time” is used unless 
specifically describing to the time to death, which is referred to as “survival time.”  
2.2.1 Data Sets 
Two real and one simulated data set were used as the basis of the investigation 
(Table 2-1). The first two data sets (Canine and Feline) were taken from the veterinary 
literature and were selected to include data that had a “typical” distribution of outcome 
and a “typical” sample size of those published in the veterinary literature.  The third data  
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set (Sham) was simulated to have a distribution of outcomes different from the real data 
sets – but still realistic for a veterinary clinical study.   
 
Table 2-1 Data sets used to illustrate the effects of alternative methods of accounting for 
observations from euthanized animals in survival analysis. 
 
Outcome 
Data set Lost-to-
follow-up 
Alive at end 
of study 
Euthanized Dead 
 No. % No. % No. % No. % 
Data set Canine 0 0 35 50 30 43 5 7 
N=70         
disease  - - - - 14 20 0 0 
Unrelated   - - - - 6 9 4 6 
unknown  - - - - 10 14 1 1 
         
Data set Feline 3 9 3 9 16 50 10 31 
N=32         
disease  - - - - 14 44 9 28 
unrelated   - - - - 0 0 1 3 
unknown  - - - - 2 6 0 0 
         
Data set Sham 7 7 10 10 20 20 63 63 
N=100         
disease  - - - - 15 15 43 43 
unrelated   - - - - 3 3 15 15 
unknown  - - - - 2 2 5 5 
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Each data set included a two-level stratification variable (either treatment or 
tumor type) to allow investigation of the effect of the alternative protocols on between-
strata comparisons.   This feature was examined because most clinical studies are directed 
at comparing treatments (or responses of different diseases or tumor types to the same 
treatment) with a conclusion drawn according to such.   
2.2.2 Data Set Canine  
Data set Canine was acquired by the primary investigator from collaborators of a 
previous investigation (Jaffe, et al., 2000). The raw data were used and any missing 
survival times were replaced with randomly generated numbers between 1 and 1000  
from a random-number table.  The stratum variable referred to treatment. Survival time 
was in days. 
2.2.3 Data Set Feline 
Data set Feline was acquired directly from published information (Cox, et al., 
1991) and again, any missing survival times were replaced with randomly generated 
numbers between 1 and 30 from a random-number table.  The stratum variable referred to 
tumor type.  Survival time was in months. 
2.2.4 Data Set Sham  
Data set Sham was created to have a greater proportion of animals that died from 
the disease of interest and fewer animals alive at the end of the study than data sets 
Canine and Feline -- but still have a moderate proportion of animals that were euthanized.  
N = 100 was chosen to allow evaluation of a larger data set -- but use a number that is 
attainable for a clinical study.  After the outcome distribution was established, 100 
observations within the range of 0 to 1000 days (to disperse the observations) were 
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generated using a random-number feature of a statistical programa. A second list of 
random numbers was generated and the observations were ordered according to this list.  
The distribution of the outcome was then applied according to this order.  A third list of 
random numbers was generated and listed against the original observations for the 
purpose of designating the stratum variable (eg. treatment, tumor type, animal 
characteristic)–observations associated with an odd random number were applied to 
stratum 1; observations associated with an even random number were applied to stratum 
2.     
2.2.5 Data Sets Sham 50, Sham 20, Sham 10 
Because randomization is likely to produce strata within the simulated data set 
that are not different, data set Sham was modified to create three new data sets with a pre-
determined difference in the magnitude of the observations between strata.   The 
observations for stratum 1 were multiplied by factors of 0.5, 0.8 and 0.9 to create data sets  
Sham 50, Sham 20 and Sham 10 which had pre-determined differences between strata of 
magnitude 50, 20 and 10% , respectively.   The distribution of outcomes was unchanged.  
2.2.6 Protocols 
For each data set, seven alternative protocols for observations from animals that 
were euthanized or animals that died were explored (Table 2-2).  Protocols 1,4,5,6 and 7 
were derived from methods described in published studies that either ignored (deleted) 
observations from euthanized animals or animals that died from other causes, or equated 
euthanized animals with those that died.  Protocols 2 and 3 were explored to illustrate the 
effect of right-censoring observations from animals that were euthanized or died from  
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other causes.  Incomplete observations from animals that were alive or lost-to-follow-up 
were right-censored for all protocols (Lee, 1992a, Leung, et al., 1997).   
 
 
Table 2-2 Methods of accounting for observations from euthanized or dead animals as 
complete or right-censored (incomplete) using seven alternative protocols.  Observations 
from animals lost-to-follow-up or alive at the end of the study were considered right-
censored for each protocols. aA = all causes, D = disease of interest, U = unknown causes, 
O = known causes other  than the disease of interest, None = no observations from 
animals with this event included in this definition. Note A=D+U+O 
 
 Definition 
Protocol  Complete observations Right-censored observations 
 Event Causea Event Cause 
1 Died 
Euthanized 
A 
A 
Died 
Euthanized 
None 
None 
2 Died 
Euthanized 
A 
None 
Died 
Euthanized 
None 
A   
3 Died 
Euthanized 
D + U  
None 
Died 
Euthanized  
O 
A 
4 Died 
Euthanized 
A 
None 
Died 
Euthanized 
None 
A  -- deleted 
5 Died  
Euthanized 
D + U 
None 
Died 
Euthanized  
O -- deleted  
A -- deleted 
6 Died 
Euthanized 
A 
D + U 
Died 
Euthanized  
None 
O  
7 Died 
Euthanized 
D + U 
D + U 
Died 
Euthanized 
O  
O 
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2.2.7 Analysis 
All survival functions were estimated using nonparametric Kaplan-Meier product-
limit methods (Lee, 1992b).  For each protocol, the survival functions for the two strata 
were estimated and tested for homogeneity using the log-rank test.  All tests for 
homogeneity of survival functions were performed using a two-sided hypothesis against 
the null hypothesis of homogeneity.  Alpha  was  P < 0.05.  For each protocol, the 
stratum-specific estimates of median survival times with a 95% confidence interval 
according to Greenwood’s formula (Greenwood, 1926) were generated.  PROC 
LIFETEST (SAS v6.12, SAS Institute, Cary, NC) was used for all analyses.   
2.3 Results 
All stratum-specific estimates and comparisons are summarized in Tables 3 to 8. 
All protocols produced the conclusion of homogeneous strata for data sets Canine, Sham, 
and Sham 10, and of non-homogeneous strata for data set Sham 50 (Table 2-3, Table 2-5, 
Table 2-6).  However, there was reversal of the magnitude of the point estimates for some 
of the strata. (e.g. Data  set Canine: the point estimate for stratum 2 was higher than for 
stratum 1 with protocol 1 but the opposite for protocol  5, 6 and  7.)    
The protocols altered the conclusions for stratum comparisons for data sets Feline 
and  Sham 20 (Table 2-4, Table 2-7, Figure 2-1). (e.g. Data set Sham 20: protocols 3 and 
5 resulted in a conclusion of homogeneous strata while the other protocols resulted in a 
conclusion of non-homogeneous strata.).   
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Table 2-3 Comparisons of stratified survival-functions with the different protocols on 
data set Canine.  Survival time is in days.  Data set taken from Jaffe et al., 2000. See 
Table 2-2 for definitions of protocols.  aCI = confidence interval; bNE = not estimable 
because the probability of survival never decreased to 0.5 
 
 Stratum 1 
 
Stratum 2 
 
Homo-
geneity 
of  strata  
Protocol  Median  
 
95% CIa Censored       
fraction   % 
Median  
 
95% CI Censored       
fraction   % 
(log-
rank P) 
1 692 462, 1924 21/43 49 721 300, 874 14/27   52 0.44 
2 NEb - 40/43 93 NE - 26/27   96 0.99 
3 NE - 41/43 95 NE - 27/27 100 0.34 
4 NE - 21/24 87 NE - 14/16   88 0.50 
5 NE - 21/22 95 NE - 14/14 100 0.48 
6 1675 473,  NE 24/43 56 821 300, NE 16/27   59 0.50 
7 1924 473,  NE 26/43 60 821 721, NE 18/27   67 0.76 
 
 
 
Table 2-4 Comparisons of stratified survival-functions with the different protocols on 
data set Feline. Survival time is in months. Data set taken from Cox et al., 1991. See 
Table 2-2 for definitions of protocols. aCI = confidence interval; bNE = not estimable 
because the probability of survival never decreased to 0.5 
 
 Stratum 1 Stratum 2 Homo-
geneity 
of  
strata 
Protocol  Median  
 
95% CIa Censored       
fraction   % 
Median  
 
95% CI Censored     
fraction   % 
(log-
rank P) 
1 2.5 0.8, 11 2/16 12 12.5 5, 33 4/16   25 0.03 
2 11 3, NEb 9/16 56 NE - 13/16 81 0.04 
3 11 3, NE 9/16 56 NE - 14/16 88 0.01 
4 3 0.8, NE 2/9   22 NE - 4/7     57 0.07 
5 3 0.8, 11 2/9   22 NE - 4/6     67 0.03 
6 2.5 0.8 ,  11 2/16 12 12.5 5, 33 4/16   25 0.03 
7 2.5 0.8 ,  11 2/16 12 13 7, 33 5/16   25 0.02 
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Table 2-5 Comparisons of stratified survival-functions with the different protocols on 
data set Sham, a simulated data set with pre-determined, equivalent strata. Survival time 
is in days. See Table 2-2 for definitions of protocols. aCI = confidence interval 
 
 Stratum 1 Stratum 2 Homo-
geneity 
of  strata 
Protocol  Median  
 
95% CIa Censored     
fraction   % 
Median  
 
95% CI Censored     
fraction   % 
(log-
rank P) 
1 550 402, 735 9/50   18 574 482, 710 8/50   16 0.92 
2 677 496, 865 18/50 36 619 488, 839 19/50 36 0.95 
3 810 578, 963 28/50 56 710 504, 909 24/50 48 0.53 
4 578 391, 810 9/41   22 499 382, 632 8/39   20 0.45 
5 578 285, 810 9/31   29 504 430, 632 8/34   24 0.59 
6 553 417, 750 10/50 20 580 482, 731 10/50 20 1.00 
7 640 523, 886 20/50 40 619 488, 788 15/50 30 0.54 
 
 
 
Table 2-6 Comparisons of stratified survival-functions with the different protocols on 
data set Sham 50, a simulated data set with stratum 1 having a predetermined 50% lower 
median survival time compared to stratum 2. Survival time is in days. See Table 2-2 for 
definitions of protocols. aCI = confidence interval 
 
 Stratum 1 
 
Stratum 2 
 
Homo-
geneity 
of  strata 
Protocol  Median  
 
95% CIa Censored     
fraction   % 
Median  
 
95% CI Censored     
fraction   % 
(log- 
rank P) 
1 275 202, 68 9/50   18 574 482, 710 8/50   16 0.0001 
2 338 248, 432 18/50 36 619 488, 839 19.50 36 0.0001 
3 405 289, 482 28/50 56 710 504, 909 24/50 48 0.008 
4 289 196, 405 9/41   22 499 382, 632 8/39   21 0.0001 
5 289 142, 405 9/31   29 504 430, 632 8/34   24 0.0001 
6 276 208, 375 10/50 20 580 482, 731 10/50 20 0.0001 
7 320 262, 443 20/50 40 619 488, 788 15/50 30 0.0001 
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Table 2-7 Comparisons of stratified survival-functions with the different protocols on 
data set Sham 20, a simulated data set with stratum 1 having a predetermined 20% lower 
median survival time compared to stratum 2. Survival time is in days. See Table 2-2 for 
definitions of protocols. aCI = confidence interval 
 
 Stratum 1 
 
Stratum 2 
 
Homo-
geneity 
of  strata 
Protocol  Median  
 
95% CIa Censored     
fraction   % 
Median  
 
95% CI Censored     
fraction   % 
(log-
rank P) 
1 440 321, 588 9/50   18 574 482, 710 8/50   16 0.008 
2 542 396, 692 18/50 36 619 488, 839 19/50 36 0.02 
3 648 462, 770 28/50 56 710 504, 909 24/50 48 0.26 
4 462 313, 648 9/41   22 499 382, 632 8/39   20 0.08 
5 462 228, 648 9/31   29 504 430, 632 8/34   24 0.16 
6 442 334, 600 10/50 20 580 482, 731 10/50 20 0.005 
7 512 418, 788 20/50 40 619 488, 788 15/50 30 0.07 
 
 
Table 2-8 Comparisons of stratified survival-functions with the different protocols on 
data set Sham 10, a simulated data set with stratum 1 having a predetermined 10% lower 
median survival time compared to stratum 2. Survival time is in days. See Table 2-2 for 
definitions of protocols. aCI = confidence interval 
 
 Stratum 1 
 
Stratum 2 
 
Homo-
geneity of  
strata 
Protocol  Median  
 
95% CI Censored      
fraction   % 
Median  
 
95% CI Censored     
fraction   % 
(log- 
rank  P) 
1 495 362, 662 9/50   18 574 482, 710 8/50   16 0.11 
2 609 446, 778 18/50 36 619 488, 839 19/50 36 0.15 
3 729 520, 867 28/50 56 710 504, 909 24/50 48 0.59 
4 520 352, 729 9/41   22 499 382, 632 8/39   20 0.40 
5 520 256, 729 9/31   29 504 430, 632 8/34   24 0.47 
6 498 375, 675 10/50 20 580 482, 731 10/50 20 0.09 
7 576 471, 797 20/50 40 619 488, 788 15/50 30 0.34 
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Figure 2-1 Estimated survival functions S(t) for strata with protocol 3 (top) and protocol 6 
(bottom) for data set Sham 20, a simulated data set with stratum 1 having a pre-
determined  20% lower median survival-time compared to stratum 2.  Protocol 3, required 
right-censoring observations from euthanized animals and resulted in conclusion of 
homogeneous strata (P=0.26). Protocol 6 required classing observations from euthanized 
animals as complete, except if they were euthanized for reasons other than the disease of 
interest (right-censored), and resulted in a conclusion of non-homogeneous strata 
(P=0.005).   
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2.4 Discussion 
Although there were some overlaps in the 95% confidence intervals for the 
estimates of median survival time with the different protocols, viewing only the point 
estimates in the results of our study would result in quite different conclusions.  In  
veterinary oncology, when survival times are not always long and often described  in 
months,(Cox, et al., 1991, Blackwood and Dobson, 1996, Ettinger, et al., 1998) the 
difference of one or two months in a point estimate may  be important.  Within each data 
set, the protocols that required deletion of observations (protocols 4 and  5) typically 
resulted in lower point estimates of median survival time.   
In comparison, the protocols that required a substantial number of censored 
observations (protocols, 2,3,6 and 7) often had higher point estimates of median survival 
time.  This discrepancy is important.  Deleting observations deletes important data from 
any study, and consequently presents a misleading point estimate of survival time.  
Deleting censored observations has been shown to underestimate the survival function 
and estimates of survival time (Watt, et al., 1996).  Our results support this finding 
although how much of an underestimate the result represents is unclear because the true 
estimate is unknown.   The powerful feature of survival analysis is that it has the ability to 
use information from observations that are incomplete (Lee, 1992a, Watt, et al., 1996); 
hence, protocols that delete such observations are unsatisfactory.    
Inherent to survival analysis is the reduction in confidence for the estimation of 
the upper tail of the survival distribution because the sample size progressively decreases 
over time (Kleinbaum, 1996).  Consequently, the median is the preferred measure of 
central tendency when there are right-censored observations (Kleinbaum, 1996). 
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 Protocols that required substantial right-censoring of observations frequently resulted in 
the inability to obtain estimates of median survival time because the probability of 
survival did not decrease below 0.5.  The inability to obtain estimates can pose problems 
for clinical studies that rely on estimates to summarize results and relay prognostic 
information.  Typically, as shown with the data sets in this study, veterinary studies can 
contain a large proportion of euthanized animals. In addition, there may be a moderate 
proportion of animals lost to follow-up, or that die of other causes (Shapiro, et al., 1988, 
Cox, et al., 1991, Berg, et al., 1992, Munana and Luttgen, 1998, Zwahlen, et al., 1998). 
Such studies are vulnerable to problems of unobtainable estimates when protocols that 
require right-censoring of observations are used.  
The reversal in ranking of strata appeared most often between protocols requiring 
some right-censoring (protocol 6,7) or no separation of cause of death (protocol 1) and 
protocols requiring deletions (protocol 2,3).  This reversal in the estimates shows the 
danger of deleting observations and how right-censoring will increase the estimates in 
comparison to deletion (Watt, et al., 1996). 
The most-important assumption of any censoring is that of independence, such 
that the survival time and the time of censoring are independent (Leung, et al., 1997). 
Independent censoring should be non-informative, and non-prognostic. (That is, a 
censored observation at time C indicates that the survival time exceeded C but gives no 
prognostic information about subsequent survival times of that animal or of other 
animals.)  To clarify right-censoring under these terms, it is easy to see that right-
censoring due to study  termination is likely to be independent of survival time;  however, 
right-censoring due to other reasons such as loss-to-follow-up might not be independent 
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of survival time.  Right-censoring due to euthanasia is certainly not independent of 
survival time.   If censoring is informative (not independent), then standard Kaplan-Meier 
product limit methods of estimation of the survival function is biased and methods that 
account for the informative nature of the observations must be used (Robins, 1995b, 
Robins, 1995a, Leung, et al., 1997). If the censoring time and the survival time are 
positively correlated, the Kaplan-Meier estimate will over-estimate the survival function;  
if the times are negatively correlated, then the Kaplan-Meier estimate will under-estimate 
the survival function (Leung, et al., 1997). Thus, right-censoring observations from 
euthanized animals (due to the disease) is inappropriate when the standard methods of 
survival analysis are applied (Fisher and Kanarek, 1974).   
One investigator proposed that to avoid the issue of euthanasia in analysis of 
veterinary oncology studies, the time to tumor recurrence should be used to evaluate the 
efficacy of treatment (Theon, et al., 1993). While this may avoid the issue of observations 
from euthanized animals, it only provides partial information on the effect of the tumor 
type or treatment, etc.  More importantly however, the estimation of the survival function 
or time-to-tumor-recurrence function may still be biased.  Most veterinary studies use 
right imputation of observations.  The observations are collected at intervals over time 
(usually associated with re-visits).  When observations are treated as point observations 
(which requires continuous observation), it is assumed that the occurrence of the event 
coincides with the reporting of the event (right imputation).  In reality, the simultaneous 
occurrence of the event and the re-visit is unlikely and making the assumption of 
coincidence will lead to biased estimates (Leung, et al., 1997). Right imputation has more 
effect when the intervals are wide and represent a substantial proportion of the overall 
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observation period (Leung, et al., 1997), or when the intervals are not independent of the 
event (e.g. a revisit is prompted by a change in the animal’s condition).   
2.5 Conclusion 
The protocols applied in current veterinary studies to account for observations 
from euthanized animals, and in some cases, from animals that die or are lost-to-follow-
up, are inadequate and likely to present biased results.  When observations from animals 
that are euthanized are used as complete observations -- even if the protocols applied are 
the same between studies -- the equation is erroneous because euthanasia as an arbitrary 
end point (and, hence, inconsistent among studies and even among observations).  Right-
censoring observations from animals that are euthanized would provide uniformity 
among investigations; however, methods of analysis that account for the informative 
nature of the time-of-euthanasia must be used.   
2.6 Notes 
aSAS Version 6.12, SAS Institute, Cary, NC.   
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CHAPTER 3 ESTIMATION OF HEALTH-RELATED SURVIVAL USING A 
MARKOV MODEL IN A COHORT OF DOGS WITH GENERALIZED 
LYMPHOMA  
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3.1 Introduction 
One of the most common measurements used to describe clinical disease, 
particularly cancer, is survival time or time to other important event such as tumor 
recurrence (Thompson and Fugent, 1992, Hammer, et al., 1995, Al-Sarraf, et al., 1996, 
Straw, et al., 1996, Kuntz, et al., 1997, Levy, et al., 1997, Slawienski, et al., 1997, 
Khanna, et al., 1998, Zwahlen, et al., 1998). There has been recent concern over how 
some clinical studies published in the veterinary literature have been interpreted 
(Pitson, 2000). Time-event studies, collectively known as “survival studies” present 
two concerns: 1) survival estimates may contain substantial inherent bias, as 
demonstrated recently by the authors, (Hosgood and Scholl, 2000)   and 2) survival 
estimates provide only quantitative estimates of the survival time.  
Most veterinary studies evaluate time-event data using non-parametric Kaplan-
Meier product limit estimation (Thompson and Fugent, 1992, Al-Sarraf, et al., 1996, 
Blackwood and Dobson, 1996, Kuntz, et al., 1997, Levy, et al., 1997, Dunning, et al., 
1998, Khanna, et al., 1998) or Cox proportional hazards estimation (Johnson, et al., 
1989, Spodnick, et al., 1992, Hammer, et al., 1995, Slater, et al., 2001). Unfortunately, 
the Kaplan-Meier estimator is sensitive to methods of classifying euthanized animals, 
animals lost to follow-up, or in some cases, animals dying from other causes (Hosgood 
and Scholl, 2000).  Euthanasia represents an arbitrary end point determined by the 
owner and veterinarian (Gobar, et al., 1998, Mallery, et al., 1999) and does not 
precisely equate to the time of natural death. In an attempt to manage the problem, 
investigators have used a variety of protocols, including deleting or censoring such 
observations or simply equating them with death (Al-Sarraf, et al., 1996, Kuntz, et al., 
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1997, Dunning, et al., 1998, Khanna, et al., 1998). These protocols yield biased and 
misleading estimates of survival time (Hosgood and Scholl, 2000).  While censoring 
observations from euthanized animals appears a plausible solution, such observations 
are informative and neither Kaplan-Meier or Cox proportional hazards estimation are 
appropriate since the underlying assumption of these methods is that censoring is 
uninformative, that is, independent of survival time (Collett, 1994).  Interestingly, 
some investigators deny that a problem exists and dismiss observations from 
euthanized animals as being usual for any clinical data set and hence the variability 
this presents is natural (Slater, et al., 2001).  
A survival estimate provides a quantitative description of the course of the 
disease till the recognized outcome, which can be used as a measurement to compare 
treatment success or failure.  However, it conveys no information of the animals’ 
condition during the survival time. The animals’ health and well-being, particularly 
under alternative treatments, are issues that are very important to veterinarians and 
owners and may substantially influence decision making. 
An alternate strategy to evaluate time-event data is the use of Markov 
modeling. Markov modeling is a form of stochastic modeling (one which models 
random events) used in diverse fields areas such as computer science, engineering, 
mathematics, genetics, agriculture economics, education and biology (Hillis, et al., 
1986, Jain, 1986, Stewart, 1994).  Markov modeling has received considerable 
attention in the evaluation of human disease. For example, it has been used in the 
evaluation and description of  diabetic retinopathy (Marshall and Jones, 1995), 
systemic lupus erythematosus (Silverstein, et al., 1988), renal disease (Schaubel, et al.,
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 1998), papilloma virus and human immunodeficiency virus (Hendriks, et al., 1996).  
Markov modeling is the basis for decision making analysis (Sonnenberg and Beck, 
1993). As evaluation of quality–of-life and health-related states in human cancer 
studies is explored (Bowling, 1995, Bradlyn and Pollock, 1996, Bowling, 1997, 
Glasziou, et al., 1998), Markov modeling continues to be the basis for evaluation of 
such data (Olschewski and Schumacher, 1990, Stewart, et al., 1998, Ng, et al., 1999, 
Aoki, et al., 2000).  
The intent of this study was to create a Markov model to describe the health-
related survival in a cohort of dogs with generalized lymphoma and use the model to 
estimate survival time. The cohort contained a substantial number of animals that were 
euthanized or were lost to follow-up.   
3.2 Methods 
3.2.1 Data  
Data from the medical records of 64 cases of generalized lymphoma seen at 
Louisiana State University Veterinary Teaching Hospital and Clinic between 1990 and 
2000 was used for this study.  Inclusion criterion was that the dog had a diagnosis of 
generalized lymphoma confirmed by histology or cytology.   
Information extracted from the records included clinical signs and hematologic 
data.  This data was entered into a data basea and used for health-state classification.  
Each visit for each dog represented a single record.    
3.2.2 Health State Definition, Classification and Validation  
Five health states were defined: two transient states and three absorbing states  
 
(Table 3-1).   
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Table 3-1 Definition of health states to describe dogs with lymphoma. *TOXIC = 
presence of clinical or hematologic changes; **WELL = absence of clinical signs or 
hematologic changes. 
 
State Definition Type 
TOXIC* Toxic  Transient 
WELL** Well  Transient 
EUTH Euthanized Absorbing 
DEAD Dead Absorbing 
LTF Lost to follow-up Absorbing 
 
 
The definition of TOXIC was based on previous discussion of toxicity with 
lymphoma (Table 3-2) (van Vechten, et al., 1990, Hahn, et al., 1992, Moore, et al., 
1994, Ruslander, et al., 1994, Myers III, et al., 1997, Khanna, et al., 1998, Lucroy, et 
al., 1998, Zemann, et al., 1998, Lucroy and Madewell, 1999, Frimberger, 2000).   
The definition of health states was constructed such that the states were 
mutually exclusive. A dog was classified in TOXIC if one or more of the hematologic 
or clinical abnormalities listed were present (Table 3-2).  A dog was classified in 
WELL is none of the hematologic or clinical abnormalities listed were present (Table 
3-2).  TOXIC represented a state where there are moderate to severe clinical signs that 
compromise the animal or where hematologic changes are severe enough to have an 
impending impact on the dogs health and the likelihood of continued treatment. There 
was no attempt to differentiate whether toxicity was a result of treatment or disease. 
There was no attempt to determine whether WELL represented a disease-free or 
remission state, or a state where the animal was tolerating the disease.  
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Table 3-2 Definition of toxicity (TOXIC) health state classification. Presence of one or 
more of these conditions was sufficient to classify a animal as TOXIC. 
*Lymphadenopathy was not considered a toxic change. 
 
Condition representing toxicity * Definition 
CLINICAL SIGNS 
   Body weight  Weight loss on history of presentation 
 Weight loss >5% since last visit 
   Vomiting >3 times per day or requiring fluid therapy 
for > 2 days 
   Diarrhea Persistent (>3 days) or requiring fluid 
therapy for > 2 days 
   Appetite  Complete anorexia  
   Activity  Inactivity – not willing to move around 
voluntarily except to defecate or  urinate 
   Cardiac toxicity Clinical signs of cardiac failure and 
echocardiographic evidence of decreased 
contractility with or without heart chamber 
enlargement 
HEMATOLOGY 
   Platelets <125,000 cells/dl 
   Red blood cells  PCV < 25% 
   Blood urea nitrogen  >50 g/dl 
   White blood cells  <3500 cells/dl 
   Neutrophils  <2500 cells/dl 
SUPPORTIVE CARE 
 Fluid therapy > 2 days 
 Any other condition requiring intensive 
care hospitalization >2 days 
 
A subset of 15 cases (58 cycles) were classified by two other veterinarians to 
evaluate the agreement between raters. Calculation of the chance corrected agreement 
allowed estimation of misclassification due to imprecision using the scheme (Dunn,  
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 1989).  In addition, these cases were re-classified by the PI and two veterinarians at 
least one month later to estimate intra-rater repeatability (intraclass correlation 
coefficient) (Rosner, 1995) of the classification scheme.   
3.2.3 Markov Estimation and Analysis 
A 5 state, discrete, time homogeneous Markov chain was constructed.  Each 
dog’s survival interval was divided into 7-day cycles that were assigned a single 
health-state (Figure 3-1).   
 
EUTH DEAD LTF 
WELL TOXIC 
 
 
 
 
Figure 3-1 Five state Markov chain with two transition states (TOXIC, WELL) and 
three absorbing states (EUTH = euthanized, DEAD = died due to disease, LTF = lost-
to-follow-up). 
 
The transitions of the Markov chain were summarized by constructing a 
transition probability matrix.  The progression of the disease was described by a 
transition analysis of the Markov chain that required sequential multiplication of the 
transition probability matrix. The probability matrix was then manipulated to estimate 
residence (survival) times in each state and subsequently summed to estimate overall 
survival time. For comparison purposes, Monte-Carlo simulation of the Markov chain 
based on the estimated transition probabilities was also performed to generate 
estimates of survival times.   
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3.2.4 Probability Matrix 
For each cycle, a count matrix was constructed based on the number of dogs 
making the respective transitions. The count matrices were summated to give the 
overall summation (S) matrix (Jain, 1986).  The summation matrix was used to 
construct the probability (P) matrix using maximum likelihood estimates of  , the 
probability of transition from state i, the previous state, to state j, the future state, 
given by 
ˆ ijp
( ) ( ).ˆ ij ij ip f k f k=  where  is the frequency or count of dogs making the 
transition from state i to state j,  is the sum of dogs initially in state i and k is the 
cycle with a total of K cycles (Figure 3-2) (Craig and Sendi, 2001).  Hence, the sum of 
each row of the P matrix is one (Jain, 1986).  
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Figure 3-2 Summation matrix (S) and probability matrix (P).  
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3.2.5 Time Homogeneity Assumption 
The assumption of homogeneity of transition probabilities across time cycles 
was tested using the likelihood-ratio chi square statistic which tests the parameter 
values that maximize the likelihood function under the assumption that the null 
hypothesis (there is homogeneity across time strata) is true (Kalbfleisch and Lawless, 
1985, Jain, 1986, Agresti, 1996). Thus, the test is based on the ratio of the maximized 
likelihoods when parameters satisfy the null hypothesis to the maximum likelihood 
when the parameters are unrestricted (in the sample).  
The assumption of homogeneity was evaluated over all cycles and within 
certain periods (cycles 1-25, cycles 26-50 and cycles 51+).  In addition, the data was 
collapsed for each of the above periods, and the assumption of homogeneity was 
evaluated across the three periods.  
3.2.6 N Step Transition Analysis  
The progression of the disease can be described by performing a transition 
analysis (Silverstein, et al., 1988).  The probability of being in a given state after n 
steps or cycles is calculated by P where n is the number of cycles. The N-step 
transition analysis was performed over successive cycles until absorption was 
complete. The probabilities of being in each transient or absorbing state, was recorded 
at each cycle.      
n
3.2.7 Residence (Survival) Time in Each Transient State 
An estimate of the overall survival time can be made by summing the 
estimated average number of cycles that an animal resided in both of the transient 
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states.  The average number of cycles that an animal resided in either of the transient 
states was estimated using matrix algebra and Monte Carlo simulation (Beck and  
Pauker, 1983, Sonnenberg and Beck, 1993, Briggs and Sculpher, 1998, Meerschaert, 
1999).  
Matrix algebra - The transition probability matrix of a chain that contains 
absorbing states can be divided into four sections: the section labeled Q reflects the 
probability of not being absorbed, conditional on the starting state; the section R 
reflects the probability of being absorbed; the section O is a zero matrix, and section I 
is an identity matrix (Figure 3-3) (Beck and Pauker, 1983, Brown and Brown, 1990a).  
 
  To: 
  Transient  
States 
Absorbing  
States 
Transient 
States 
 
 
 
Q 
 
R 
 
 
From: 
Absorbing  
States 
 
 
 
O 
 
I 
 
Figure 3-3 Separation of a probability transition matrix containing absorbing states 
into 4 components --  Q is the probability of not being absorbed, conditional on the 
starting state; R is the probability of being absorbed; O is a zero matrix, and section I 
is an identity matrix. 
 
The average number of cycles that an animal resided in either transient state 
before absorption, given a specified starting state, was estimated from the fundamental 
(N) matrix. Calculation of N is the matrix algebraic equivalent of taking the inverse of 
the transition probability (Beck and Pauker, 1983, Brown and Brown, 1990b). 
Calculation of N is explained by Beck (Beck and Pauker, 1983). N specifies the 
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number of cycles that animals resided in the transient states such that  
where I is the identity matrix and  Q is the square matrix of the transient probabilities 
within P (Appendix I) (Beck and Pauker, 1983, Brown and Brown, 1990b).  
( )-1N = I - Q
The variance of N is given by the V matrix with  where 
is a copy of N with only the diagonal entries preserved (and zeroes elsewhere) and 
is a matrix with each entry of N squared (Appendix II)  (Beck and Pauker, 1983, 
Silverstein, et al., 1988). Each element of V represents the variance of the 
corresponding element of N. The square root of each element of V was used as the 
standard error of the corresponding element of N. 
( )′ 2V = Ν 2Ν - Ι -Ν
′N
2N
 Estimation of residence/survival times by Monte Carlo estimation - One 
hundred simulations were started from TOXIC and 100 simulations were started from 
WELL, each continuing until the chain terminated in an absorbing state (Beck and 
Pauker, 1983, Briggs and Sculpher, 1998, Meerschaert, 1999).  The mean residence 
time in each transition state, conditional on the starting state, was calculated from the 
individual transition simulations.  The mean survival time, conditional on the starting 
state was calculated from the sum of the residence time in each transition state from 
the individual transition simulations.  A weighted mean of the conditional survival 
times was then calculated to give an overall survival time, weighted according to the 
distribution of the starting states in the cohort; that is the conditional survival time for 
starting in TOXIC was weighted by a factor of 0.5625 and the conditional survival 
time for starting in TOXIC was weighted by a factor of 0.4375 before summing the 
two estimates.  The variance of this weighted estimate was calculated as the variance 
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of a sum;  σ σ  (Neter, et al., 1982) and 
used to calculate the 95% confidence interval of the weighted estimate. The frequency 
of absorption into the three different absorbing states, conditional on the starting state, 
was recorded.   
( ) ( ) ( ) (2 2 2 2 2 2aX bY a X b Y ab XYσ+ = + + )σ
All matrix manipulations were performed using MatLabb and Markov Chain 
Add-in for  Excel Spreadsheetsc. 
3.2.8 Survival Analysis 
Survival analysis was also performed to compare and contrast with Markov 
model analysis. Kaplan-Meier product limit estimation of a survival function of the 
cohort was performed using PROC LIFETESTd. Observations from dogs that were 
lost to follow-up or died due to other causes were right censored  (Lee, 1992a).  
Observations from all dogs that were euthanized and dogs that died due to lymphoma 
were considered complete.  The mean and median survival times were estimated from 
the survival function.  
3.2.9  Verification of Markov Estimates  
A valid estimate of the survival time can only come from complete 
observations. With such data, the estimate of the mean survival time using Kaplan-
Meier product limit methods will equal the true arithmetic mean of the observations. 
Thus, estimates derived from a Markov model constructed from complete observations 
should be similar to the arithmetic (and Kaplan-Meier estimate) of survival time. To 
verify the estimates of residence time from the discrete, time homogenous Markov 
model used in this study, observations from the subset of dogs that died (n=16) were 
used to construct the “dead” probability matrix (Pd) and its fundamental matrix (Nd). 
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In addition, using the probabilities from Pd to perform Monte Carlo simulation, 100 
simulations were performed starting from TOXIC and 100 simulations were 
performed starting from WELL, continuing until the chain terminated in an absorbing 
state (Beck and Pauker, 1983). The mean residence time in each transition state, and 
survival times, conditional on the starting states, were estimated.  A weighted mean 
overall survival time was then calculated as described previously.  The Markov 
estimates of the survival time were compared to the 95% confidence interval of the 
mean and median survival times of the restricted cohort estimated from the Kaplan-
Meier product limit analysis.   
3.3 Results  
3.3.1 Health State Testing 
There was 100% agreement in health state classification among the 3 raters 
indicating there was very little chance of misclassification.  In addition, intra-rater 
agreement was 100%, indicating the health state classification was repeatable within 
raters. 
3.3.2 Markov Modeling 
Data from 64 dogs was included for all analyzes.  Thirty-six dogs (56.25%) 
entered the study in TOXIC and 28 dogs (43.75%) entered in WELL. There were a 
total of 1218 transitions with an average of 19.03 transitions per dog.  The maximum 
number of transitions by any dog was 167.  During the progression of disease, many 
transitions were made back and forth between TOXIC and WELL. Sixteen dogs (25%) 
died due to lymphoma, 30 dogs (47%) were euthanized and 18 dogs (28%) were lost 
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to follow-up. Of the dogs lost to follow-up, 10 dogs were in TOXIC and 8 dogs were 
in WELL.  
3.3.3 Probability Matrix 
The S and P matrices are shown in Figure 3-4. 
 
Toxic Well Euth Dead LTF
Toxic 231 53 19 10 10 323
Well 57 813 11 6 8 895
Euth 0 0 0 0 0 0
Dead 0 0 0 0 0 0
LTF 0 0 0 0 0 0
∑    =       
S
 
Toxic Well Euth Dead LTF
Toxic 0.715 0.164 0.059 0.031 0.031 1
Well 0.064 0.908 0.012 0.007 0.009 1
Euth 0 0 1 0 0 1
Dead 0 0 0 1 0
LTF 0 0 0 0 1 1
∑    =       
P
1
 
Figure 3-4 Summation (S) and transition probability (P) matrices. 
 
  
3.3.4 Time Homogeneity Assumption  
Evaluation across the entire number of cycles did not result in rejection of the 
null hypothesis of homogeneity at P<0.05 (χ2=628, df=1458) however the validity of 
the test is questioned since the density of the data is thin, particularly in the later 
cycles.  When the data was divided into three periods, from cycles 1-25 (54% of data, 
26-50 (23% of data) and 50+ (26% of data), the null hypothesis of homogeneity across 
cycles within each period was not rejected at P<0.05 (χ2=193, df=207; χ2=96, df=168;  
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χ2=223, df=707 respectively).  When the data was collapsed within each of these 
periods, the null hypothesis of homogeneity across these periods was not rejected at 
P<0.05 (χ2=23, df=18).  Thus, for the purposes of this investigation, the assumption of 
homogeneity of transitions over time was considered satisfied.  
3.3.5 N Step Transition Analysis 
The probabilities of being in any one state at any time (step) are displayed 
graphically in Figure 3-5. Complete absorption occurred by 100 cycles. 
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Figure 3-5 N step transition analysis of a Markov model of canine lymphoma 
depicting progression of the disease.  The health states TOXIC, WELL, EUTH 
(euthanasia), DEAD (dead) and LTF (lost-to-followup) are defined in Table 3-1 and 
Table 3-2. 
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Note that the probabilities of residing in a transient state decrease over time 
and the probability of absorption increase such that eventually all animals are 
absorbed. Starting in TOXIC, the probabilities of being in TOXIC are higher initially, 
but after 4 steps (28 days), the probability of being in WELL is higher.  The 
probability of being in WELL then dominates until step 14 (98 days).  Thus, even if 
the dog presents in the TOXIC, the longer the dog lives, the more likely it is to reside 
in WELL. After step 14, the probability of being euthanized is highest and remains the 
highest for all absorbing states. Note that as time goes on, the probability of dying or 
being LTF also increases but remains less than that for euthanasia.  
Starting in WELL, the probability of being in WELL remains much higher 
than had the dog entered in TOXIC. The probability of being in WELL remains higher 
than being in TOXIC for the entire analysis. At step 23 (161 days), the probability of 
being in Euthanasia exceeds that of being in WELL and remains the highest for all 
absorbing states. At step 31 (217 days) the probability of DEAD exceeds that of being 
in WELL. Again, as time goes on, the probability of being LTF increases. 
3.3.6 Residence Time in Each Transient State 
Matrix inversion - The estimated mean number of cycles an animal resided in 
each transient state given by N and the variance and standard error of those estimates 
given by V and SE are shown in Figure 3-6.  After multiplying the estimated number 
of cycles by 7, the estimated residence times and 95% confidence intervals in days are 
shown in Figure 3-7. 
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TOXIC WELL
TOXIC 5.86 10.49
WELL 4.07 18.20
  =    
N
TOXIC WELL
TOXIC 2.01 8.54
WELL 1.75 14.04
  =    
V
 
TOXIC WELL
TOXIC 1.17 1.77
WELL 0.36 3.66
  =    
SE
 
Figure 3-6 Estimated mean number of cycles (N) an animal resided in each transient 
state. V is the variance and SE is the standard error of those estimates.  
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N
 
Figure 3-7 Estimated mean number of days (95% Confidence interval) an animal 
resided in each transient state.  
 
 
Thus, a dog starting in TOXIC was estimated to survive 114 days (95%CI 74-
155), and starting in WELL 156 days (95% CI 101-211). Weighting these conditional 
survival times according to the distribution of dogs starting the study in each state (ie. 
114.4 x 0.5625 + 155.9 x 0.4375), gave a weighted survival time of 133 days.  
Estimation of residence/survival times using Monte Carlo simulation - The 
estimated survival time, derived from summation of residence times in both transient 
states, conditional on starting the chain in TOXIC was 105 days (95% CI 82-128) 
(Table 3-3). This was shorter than the estimate conditional on starting the chain in  
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WELL which had a mean survival time of 137.8 days (95% CI 112-164). The 
weighted overall survival time was 119 days (95% CI 110-128).  The absorbing state 
for observations starting in TOXIC was 50 EUTH, 25 DEAD and 25 LTF. The 
absorbing state for observations starting in WELL was 48 EUTH, 31 DEAD and 21 
LTF.   
 
Table 3-3 Mean estimated residence times (95% Confidence interval) in specified 
heath states given a specified starting state.  The weighted mean, based on the 
distribution of starting states in the cohort, was used to calculate the estimated of the 
weighted overall survival time. 
 
Starting 
state 
Residence in 
TOXIC 
Residence in 
WELL  
Conditional 
survival  
Weighted overall 
survival  
TOXIC 
(n=100) 
28 days 
(22-34) 
77 days 
(55.6-97.4) 
105 days 
(82-128) 
WELL 
(n=100) 
27 days 
(20-33) 
111 days 
(88-134) 
138 days 
(112-164) 
 
119 days 
(110-128) 
 
 
3.3.7 Survival Analysis 
Kaplan-Meier estimation - No dogs died or were euthanized for causes other 
than lymphoma. Kaplan-Meier estimation of the survival curve with all observations 
from dogs dying or euthanized considered complete, and observations from dogs lost-
to-follow-up right censored resulted in a point estimate of the median survival time as 
72 days (95% confidence interval 58-152 days). The mean survival time was 201 days 
(95% confidence interval 119-284 days). Forty-six observations were complete and 18 
observations were right censored (28.1%) (Figure 3-8).  
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Figure 3-8 Kaplan-Meier product limit estimation of the survival function for canine 
lymphoma where observations from records terminating in euthanasia or death due to 
lymphoma were considered complete.  Observations from dogs lost-to-followup were 
right censored. No dogs died from other causes. 
 
3.3.8 Verification of Residence Time Estimates 
Utilizing the subset of dogs that died, twelve of these dogs (75%) entered the 
study in TOXIC, 4 dogs (25%) entered in WELL. The Sd and Pd are shown in Figure 
3-9. 
TOXIC WELL DEAD
TOXIC 79 26 10 115
WELL 25 164 6 195
DEAD 0 0 0 0
∑   =    
dS
 
TOXIC WELL DEAD
TOXIC 0.687 0.226 0.087
WELL 0.128 0.841 0.031
DEAD 0 0 1
   =    
dP
 
Figure 3-9 Summation (Sd) and transition probability (Pd) matrices for the subset of 
dogs that died. 
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The Nd, Vd and SEd are shown in Figure 3-10. After multiplying the estimated 
number of cycles by 7, the estimated residence times and 95% confidence intervals in 
days are shown in Figure 3-11.  
TOXIC WELL
TOXIC 7.65 10.88
WELL 6.17 15.06
  =    
dN
TOXIC WELL
TOXIC 1.54 2.71
WELL 1.51 3.09
  =    
dV
 
TOXIC WELL
TOXIC 0.94 1.08
WELL 0.60 1.56
  =    
dSE
 
Figure 3-10 Estimated mean number of cycles (Nd) an animal resided in each transient 
state for the subset of dogs that died. Vd is the variance and SEd is the standard error of 
those estimates. 
 
 
Toxic Well
54 76 130
(days) Toxic
(41-66 (61-91) (102 157)
43 105 149
Well
(35 51) (84 127) (119 178)
   ∑  =   −   − − −  
dN
 
Figure 3-11 Estimated mean number of days (95% Confidence interval) an animal 
resided in each transient state for the subset of dogs that died. 
 
Weighting these estimates in Figure 3-11 according to the number of dogs 
starting the study in each state, gave a weighted survival time of 135 days.  
The estimated residence time in each state and the estimated weighted overall 
survival time from Monte Carlo simulation of the chain based on Pd are given in Table 
3-4. The weighted overall survival time was 121 days (95% CI 114-128).  
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Table 3-4 Mean estimated residence times (days) in specified heath states given a 
specified starting state in the subset of dogs that died.  The weighted mean, based on 
the distribution of starting states in the subset, was used to calculate the estimated of 
the weighted overall survival time. 
 
Starting 
state 
Residence in 
TOXIC  
Residence in 
WELL  
Conditional  
survival  
Weighted 
overall 
survival  
TOXIC 
(n=100) 
42 days 
(35-50) 
80 days 
(63-97) 
123 days 
(101-144) 
WELL 
(n=100) 
34 
(27-40) 
83 
(69-97) 
117 
(97-136) 
 
121 
(114-128) 
 
Kaplan-Meier estimation of the survival curve for the subset for dogs that died 
resulted in a point estimate of median survival time of 53 days (95% confidence 
interval 5-171 days) and a mean survival time of 131 days (95% confidence interval 
53-209 days).   
3.4 Discussion 
The discrete-time Markov chain is a popular model used for describing the 
progression (Silverstein, et al., 1988, Esik, et al., 1997, Sendi, et al., 1999, Craig and 
Sendi, 2001) and evaluating interventions of chronic diseases (de Kruyk, et al., 1998, 
Stewart, et al., 1998, Aoki, 2000 #136, Ng, et al., 1999).   Chronic diseases can often 
be described in terms of distinct health states and the Markov chain is a simple but 
powerful model that can describe progression through these states.  In addition, the 
model is easy to construct and study through matrix manipulation and or simulation 
(Beck and Pauker, 1983, Briggs and Sculpher, 1998, Craig and Sendi, 2001).  The 
appeal of the Markov chain model in application to estimation of survival time and 
description of disease progression in veterinary studies was for several reasons. 
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Firstly it allowed inclusion of multiple outcomes: death, euthanasia and lost-to-
followup, which obviated the need for right-censoring of observations and avoided the 
problem of informative censoring of observations from euthanized animals (Hosgood 
and Scholl, 2000).  Secondly, it allowed animals to enter the study in any health state 
which obviated the need for left-censoring. The state of health on entering a cohort, 
which is often related to the stage of disease, is often ignored in veterinary clinical 
studies. Thirdly, it allowed description of the progression of disease by means of 
transition analysis rather than limiting attention to survival time only. 
Data from cases of generalized canine lymphoma were chosen to illustrate this 
methodology since this is a common cancer diagnosis that is often treated and access 
to adequate records was possible.    In addition, it is a disease that can follow a chronic 
course, allowing for transitions between health states over the course of survival.  
Also, since it is a commonly encountered and treated canine disease, the results of this 
study may have appeal to a wide audience. The study was conducted such that the 
results would be meaningful however; no attempt was made to evaluate treatment 
protocols although this can be a valuable extension of Markov model methodology.  
The transition probability matrix was plausible.  The probability of death was 
much higher from TOXIC, compared to WELL, as was the probability of euthanasia.  
The probability of residing in WELL was much higher given that the previous state 
was WELL rather than TOXIC. Interestingly, the probability of lost-to-followup was 
higher from TOXIC compared to WELL.   
The transition analysis showed the probable progression of the disease. This 
information is useful for prognosis and individual decision-making (Silverstein, et al., 
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1988, Briggs and Sculpher, 1998).  Based on the relative weight of the varying health 
states and outcomes in an owners mind, decision making may be facilitated by 
viewing such an analysis, particularly when treatment covariates are included in the 
Markov model.   
Estimation of residence time in each state, the sum of which is considered 
survival time, can be performed using matrix algebra or Monte Carlo model 
simulation (Beck and Pauker, 1983, Briggs and Sculpher, 1998, Craig and Sendi, 
2001).  Either method is relatively easy with access to appropriate software.  The 
estimates obtained by matrix algebra were again plausible.  On average, given that an 
animal starts the study WELL, they are likely to spend on average 28 days TOXIC and 
127 days WELL, for a total survival estimate of 156 days.  Note that this was longer 
than the survival estimate for an animal that started the study TOXIC.  As expected 
(since the same probabilities are used in estimation), the results obtained by Monte 
Carlo simulation were similar; on average an animal that started WELL survived 138 
days and an animal that started TOXIC survived 105 days.    
The advantage of the Monte Carlo simulation is that the more simulations 
performed, the smaller the confidence interval of the estimate (Briggs and Sculpher, 
1998).    We performed 200 individual simulations although up to 1000 or more 
simulations can be used for estimation purposes (Briggs and Sculpher, 1998).  Monte 
Carlo simulation also allows sensitivity analysis of the model with manipulation of the 
probabilities and evaluation of the resultant changes in the progression of the disease 
or outcome (Craig and Sendi, 2001).  In contrast to matrix algebra estimation, Monte 
Carlo simulation is not restricted to the time homogeneous model as probabilities 
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could be altered, depending on the time course over which the simulations are made 
(Briggs and Sculpher, 1998). 
For the purposes of comparison, conventional Kaplan-Meier product limit 
estimation was performed, equating euthanasia with death as typical of veterinary 
clinical investigations.  The authors would note however, that they believe this results 
in a biased estimate and hence this comparison is not a validation of the Markov 
model results (Hosgood and Scholl, 2000).  Despite this concern, it was noted that the 
Kaplan-Meier point estimate of mean survival of 201 days was considerably longer 
than the Markov estimates of 133 and 119 days and had an extremely wide confidence 
interval. An internal validation of the Markov model survival estimate would be the 
Markov model survival time estimate from dogs that died due to the target disease. It 
is important to realize that this sub-population of dogs may be confounded in some 
way with the outcome and that dogs that are euthanized and dogs that die may not 
necessarily follow the same distribution of potential survival time. Nevertheless, 
estimates obtained from the subpopulation of dogs that died were obtained using 
Markov estimates and Kaplan-Meier estimates.  The estimates derived from matrix 
algebra and Monte Carlo simulations (134 and 121 days respectively) were very 
similar to the Markov estimates for the entire population (133 and 119 days 
respectively) and to the Kaplan-Meier estimate for the dogs that died (131 days). The 
Kaplan-Meier estimate of mean survival was equal to the arithmetic mean of the 
survival times since all observations were complete (Lee, 1992b). The Kaplan-Meier 
estimate was however considerably less than the estimate for the entire population 
(201 days).  The similarity of the Markov estimates for the subpopulation of dogs that 
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died to the estimates for the entire population is expected since the Markov model 
truncates all absorbing states similarly.  In contrast, the data that ended in LTF was 
right-censored in Kaplan-Meier estimation, which has the effect of increasing the 
survival estimates and their confidence intervals. This discrepancy highlights the 
relative sensitivity of the Kaplan-Meier estimation methods that we had previously 
encountered (Hosgood and Scholl, 2000). In both estimations, the relative proportion 
the observations from dogs that died contributed to data used for estimation from the 
entire population are the same; 25% (310/1218 observations) for Markov estimation 
and 25% (16/64 observations) for Kaplan-Meier estimation. 
The Markov model estimates were stable and the variance of such estimates 
were less than those obtained by Kaplan-Meier estimation.  Kaplan-Meier estimation 
has been shown previously to be very sensitive to the methods by which outcomes are 
classified and to population size (Hosgood and Scholl, 2000).  The precision of the 
Markov estimates obtained by matrix algebra will be also affected by sample size 
(Silverstein, et al., 1988) with small sample sizes resulting in greater variance.  This is 
a disadvantage of the Markov methods, especially if the population is stratified and 
evaluated separately for the purpose of comparison (Silverstein, et al., 1988). In this 
situation, Monte Carlo simulation can be useful since the precision of the estimates 
can be increased by increasing the number of individual simulations (Briggs and 
Sculpher, 1998). 
While we believe the Markov model shows promise for the evaluation of 
veterinary clinical studies, there are concerns.  The underlying Markov assumption, 
that the process is memory-less, must be considered (Norris, 1997). In this study it was 
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assumed and deemed plausible that the probability of leaving the states WELL or 
TOXIC depended only on the current state they were in and was independent of how 
many times they had been in TOXIC or WELL previously.  Depending on the disease 
under investigation, and the model used, this assumption may not hold but can often 
be met by the addition of other health states. For example, if recurrence was being 
modeled, it may require states of first recurrence, second recurrence and so on if the 
probability of leaving these states was different (Sonnenberg and Beck, 1993, Briggs 
and Sculpher, 1998).   
An additional concern is that of transitional probability homogeneity across 
time.   This assumption was tested in this study and considered satisfied. However, as 
the data becomes less dense towards the latter cycles, the evaluation is less valid. 
Methods utilizing more complex mathematics allow for the utilization of time-
dependent probabilities (Marshall, 1990, Craig and Sendi, 2001) and require further 
study of their application to veterinary clinical studies.  In addition, simplification of 
the model by applying discrete time intervals requires further investigation.  Applying 
discrete intervals assumes that the transition occurred at the end of the interval when 
in fact it may have occurred anywhere within the interval. The larger the interval, the 
more information that is lost and the more inaccurate the estimates of survival are 
likely to be (Sonnenberg, 1985, Briggs and Sculpher, 1998, Bauerle, et al., 2000).  
Methods such as half-cycle correction can be applied, particularly when large cycles 
intervals are being used (Briggs and Sculpher, 1998).  Another issue related to 
transition intervals is the inconsistency of observations of the animals compared to the 
transition cycles. Clinical studies do not often involve clear, discrete intervals of
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evaluation and evaluation of animals are often prompted by changes in status. Animals 
not observed for several cycles were assumed to have remained in the previous state 
when in fact transitions may have occurred in between these observations.  In these 
situations, application of a continuous time Markov process may be more appropriate 
(Marshall, 1990, Anderson, 1991). 
Modeling the progression of canine lymphoma was accomplished using a 
Markov chain. In addition, estimates of survival time were obtained.   An important 
distinction must be made between the interpretations of the results of a Markov model 
analysis in comparison to traditional survival analysis.  The analysis of a survival 
curve provides information best suited to hypothesis testing concerning factors that 
influence the survival of subject groups, whether this be treatment or disease 
characteristics (Silverstein, et al., 1988, Briggs and Sculpher, 1998).  However, it is 
the contention of the authors that these results are misleading in veterinary studies 
since they are biased by observations from euthanized animals (Hosgood and Scholl, 
2000). The Markov analysis, in contrast, provides prognostic data best suited to 
facilitate decision making for individual subjects (Silverstein, et al., 1988, Briggs and 
Sculpher, 1998).  In addition, it provides estimates of survival time that can be 
partitioned according to the reason for loss and according to the health state of the 
animal, information again which is useful for individual decision making.  These 
estimates appear reliable.  
3.5 Notes 
aEPI 2000, Center Disease Control 
 
bMatlab, Mathworks Inc. 
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cMarkov Chain Add-in for  Excel Spreadsheets, Jensen, P.A., Bard, J. Operations 
Research Models and Methods, University of Texas. 
 
d SAS v 8.0, SAS Institute, Cary, NC. 
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4.1 Introduction 
Vaccine-associated sarcoma (VAS) is an emerging problem in the pet cat 
population (Kass, et al., 1993, Coyne, et al., 1997, Gobar and Kass, 2002) and has 
received considerable attention regarding preventative and therapeutic strategies, 
including the establishment of an American Veterinary Medical Association directed 
task force (Richards, 1997).   Results of treatment have been reported (Lester, et al., 
1996, Davidson, et al., 1997, Barber, et al., 2000, Hershey, et al., 2000, Bregazzi et al., 
2001, Cohen, et al., 2001, Kobayashi, et al 2002) and the disease appears to follows a 
chronic course regardless of treatment protocol.  Clinical studies have focused on 
hypothesis testing of treatment protocols by comparing survival time and time to 
recurrence of two or more treatment groups (Davidson, et al., 1997, Barber, et al., 
2000, Hershey, et al., 2000, Bregazzi, et al., 2001, Cohen, et al., 2001). The results of 
these studies do not clearly describe the course of VAS, or provide unbiased 
information useful for individual decision-making.   
In the clinical setting, prediction of the disease course, prognosis and the 
probability of dying are important to the veterinarian and owner.  Markov modeling is 
a form of stochastic modeling (one which models random events) used in diverse 
fields such as computer science, engineering, mathematics, genetics, agriculture 
economics, education and biology (Hillis, et al., 1986, Jain, 1986, Stewart, 1994). 
Markov modeling can be used to model progression of disease as a series of probable 
transitions through health or disease states.  Manipulation of the transition 
probabilities through matrix solution or simulation can be used to estimate the 
probable duration spent in each state. When the process ends in an absorbing state 
 94 
such as death, the summation of these durations can be used to expected survival 
(Beck and Pauker, 1983, Silverstein, et al., 1988, Briggs and Sculpher, 1998).  Since 
Markov modeling predicts the future of the process based on estimates of transition 
probabilities, it provides information suitable for individual decision-making 
(Silverstein, et al., 1988). 
This study established a Markov model to compare the progression of VAS in 
a cohort of cats undergoing different treatment protocols. Estimates of transition 
probabilities, duration spent in disease states and expected survival were compared 
between different treatment protocols.   
4.2 Methods 
4.2.1 Data  
Information retrieved from the medical records of 294 cats diagnosed with 
VAS from 1989 to 1994 at the University of California at Davis included treatment, 
and the time to recurrence, metastasis, re-treatment, death or euthanasia. Recurrence 
was defined as recurrence of the local tumor or presence of metastasis.  Each cat’s 
disease progression was recorded until the end of the study period at which time the 
cat was either alive, had died or had been euthanized. The time of last assessment for 
cats that were alive but lost to follow-up was recorded.  Cats that died or were 
euthanized for reasons other than the disease of interest were right censored and thus 
considered alive at the time of record. 
4.2.2 Treatment Groups  
The treatment protocol used for each cat was noted for the purpose of 
comparison.   Three treatment protocols were defined. NONE was defined as no 
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surgical treatment but included cats that received novel medical treatment such as 
corticosteroids, acemannin and other unspecified chemotherapy protocols.  
SURGERY (SX) was defined as surgical excision of the sarcoma.  SURGERY + 
RADIATION (SX+RAD) was defined as surgical excision with at least one radiation 
treatment within one month of surgical excision.  If a cat received radiation at any 
time in its disease course, it was categorized in the SX+RAD treatment group.  There 
was no standardized radiation protocol for cats in this study. Radiation was delivered 
using cobalt 60. 
4.2.3 Characteristics of Treatment Groups 
Age was considered continuous and found to follow a normal distribution after 
failure to reject the null hypothesis of normality at P=0.05 using the Shapiro-Wilk 
statistic.  The mean+/-SEM age of each treatment group was calculated and compared 
using a one-way ANOVA. Post-hoc comparisons using Tukey’s test were made where 
there was a significant effect of treatment.  Type I error was set a 0.05.   
An association between age and outcome was explored using proportional 
logistic regression. Age (years) was modeled as a continuous variable against the 
outcome Alive, Dead and Euthanasia.  The single, proportional odds ratio summarized 
the odds of dead versus alive and euthanasia versus dead with incremental increases in 
age.  This analysis was performed since an association between age and outcome, 
particularly euthanasia, may suggest confounding of the transition rates between 
disease states by age. If such confounding existed, the assumption of time 
homogeneity may not hold.  Significant association was considered when the 95% 
confidence interval of the proportional odds’ ratio excluded 1.0.   
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4.2.4 Markov Model 
A 5-state Markov model was constructed that included three transient states --  
ENTRY, RECURRENCE1 and RECURRENCE2+, and two absorbing states -- 
DEATH and EUTHANASIA (Figure 4-1).  ENTRY was the starting state of the 
model and corresponded to the initial presence of gross disease at the time of 
diagnosis for all cats.  Since treatment was then applied, for cats that received no 
surgery, ENTRY was characterized by the persistence of disease. For cats that 
received surgery and or radiation, ENTRY was characterized by the immediate 
condition after initial treatment. This condition could not be assumed to be disease-
free. RECURRENCE1 (RECURR1) was defined as the first documentation of 
recurrent gross disease or metastasis.  Transition into RECURR1 was only possible for 
SX or SX+RAD cats.  RECURRENCE2+  (RECURR2+) was defined as the second or 
later documentation of recurrent gross disease or metastasis.  Transition into 
RECURR2+ implied that the cat had been re-treated after the first recurrence.  
Transition into DEATH or EUTHANASIA (EUTH) was possible from ENTRY, 
RECURR1 or RECURR2+.   
Time spent in ENTRY, RECURR1 and RECURR2 implied the cats were alive 
however, this time was characterized both by presence and absence of disease of gross 
disease. It was impossible from the available data to clearly document disease-free 
time. Since the primary focus of the study was estimation of probabilities and times to 
termination, the model, as it was defined, could clearly describe these features and 
compare expected survival (with or without the presence of gross-disease) between the 
different treatment protocols.  
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Figure 4-1 A 5 state Markov model used to describe progression of vaccine-associated 
sarcoma in a cohort of 294 cats.  State ENTRY, RECURRENCE1 and 
RECURRENCE2+ are transient states. State DEATH and EUTH (Euthanasia) are 
absorbing states. The transition rates between transient states are defined as q, into 
absorbing states as u. 
 
 
4.2.5 Transition Probabilities Matrix 
Time homogeneity was assumed.  Time homogeneity implies that transition 
rates remained constant over the duration of the study, for example, that the transition 
between two states was the same for cats in March as it was in September. This was a 
plausible assumption since it was unlikely that environmental factors associated with 
the time of year would influence the course of the disease. The underlying Markovian 
assumption, that the transition from a state is dependent only on the current state and 
not where the process has been, was also assumed (Stewart, 1994).  Sequential 
recurrence states were included to avoid possible violation of the Markovian property 
since transition into a recurrence state may be dependent on whether previous 
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recurrence had occurred. It is possible that recurrence is more likely if a previous 
recurrence had occurred.  
A one month cycle was used for the Markov chain The rate of recurrence, 
dying or of being euthanized from ENTRY, RECURR1 and RECURR2+ was 
calculated as events per animal-months where ; λ/ animal-monthsi ijaλ = i  is the rate 
of moving from state i to state j and  is the number of events. The probability 
corresponding to the rate was calculated as the exponential transform;  
where λ
ija
1 itp e λ−= −
i is the rate and t is the time period for which the probability is estimated, in 
this case one month (Beck and Pauker, 1983, Silverstein, et al., 1988, Sonnenberg and 
Beck, 1993, Miller and Homan, 1994, Sahai and Khurshid, 1996).  Thus, the model 
was defined as a 5-state time homogeneous discrete Markov chain (Jensen and Bard, 
2002a). The transition probability matrices (P) for each treatment group were 
established using these probabilities. The probability of staying in the current transient 
state was calculated by subtracting the sum of all probabilities of exit from that state 
from one.  Hence, the sum of the probabilities of each row of the P matrix equaled one 
(Norris, 1997, Meerschaert, 1999).  
4.2.6 Estimation of State Durations  
Monte Carlo (individual) simulation was used preferentially over matrix 
solution for estimation of the duration spent in transient states since it affords smaller 
variance estimates.  Increasing the number of simulations can reduce the variance of 
the point estimates of duration (Silverstein, et al., 1988, Sonnenberg and Beck, 1993, 
Briggs and Sculpher, 1998).  Five hundred simulations were performed for each 
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group. Simulations started in ENTRY and continued until absorption into DEATH or 
EUTH. The mean (+/-SEM) cycles (time) spent in each state and the cumulative 
number of cycles (time) to absorption (expected survival) was calculated for each 
group.  A 95% confidence was calculated for each estimate.  The duration spent in 
transient states and the expected survival for each group were compared using a one-
way ANOVA (or t-test where appropriate). Post-hoc comparisons using Tukey’s test 
were made where there was a significant effect of treatment.  Type I error was set at 
0.05.   
4.2.7 Transient Analysis 
Progression of the model was described by a transient analysis of the P matrix 
(Silverstein, et al., 1988).  The transient analysis was performed by iterating 
 where is the vector of probabilities of being in a specified state at the 
next cycle, n+1, is the vector of probabilities at the current cycle, and  P is the 
probability matrix. The initial probability vector included a probability of 1 for 
ENTRY and 0’s elsewhere since all cats began in the ENTRY state. The transition 
analysis was iterated until the probability of being in any transient state was zero.    
1n n+ = ⋅p p P 1n+p
np
0p
4.2.8 Sensitivity Analysis 
A one-way sensitivity analysis was performed for each group to examine the 
behavior of the model under different conditions (Sendi, et al., 1999). The probability 
of staying in the transient states ENTRY, RECURR1 and RECURR2+ was increased 
from 0 to 1 in increments of 0.1.  These probabilities were adjusted since, in theory, 
staying in these states represented a curative procedure, either initially or after 
development of recurrence. Adjustment of these probabilities was most applicable to 
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the clinical situation.  All other probabilities in the matrices remained the same, except 
for the co-dependent probabilities in the same row.  The co-dependent probabilities 
were adjusted proportionally to reflect their original distribution and allow the sum of 
the row probabilities to remain equal to one. For each increment in probability, the 
adjusted expected survival was estimated using cohort simulation with 10,000 
subjects. Cohort simulation illustrates the experience of a hypothetical cohort of 
subjects as predicted by the adjusted model (Beck and Pauker, 1983, Sonnenberg and 
Beck, 1993, Briggs and Sculpher, 1998, de Kruyk, et al., 1998, Bauerle, et al., 2000). 
The entire cohort began in ENTRY. At each cycle of the model, the appropriate 
transition probabilities were applied and the distribution of subjects in each state of the 
Markov model was adjusted. The analysis continued until there were <10 subjects in 
all transient states.  The number of subjects in each transient state over the cycles was 
summed and divided by the number of original subjects (10,000) to estimate the mean 
number of cycles spent in each transient state.  The sum of the cycles spent in all 
transient states, multiplied by one month, estimated the mean expected survival for 
each adjusted probability matrix (Beck and Pauker, 1983, Sonnenberg and Beck, 1993, 
Briggs and Sculpher, 1998). 
All matrix manipulations were performed using MatLab 6a and Markov Chain 
Add-in for  Excel Spreadsheetsb. All statistical evaluations were performed using SAS 
v 8.0c (PROC LOGISTIC, PROC GLM, PROC UNIVARIATE).   
4.3 Results 
Fifty-nine cats were categorized in group NONE, 208 cats in SX and 27 cats in 
SX+RAD. One hundred cats were alive at the end of the study, 25 died and 169 were 
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euthanized. Cats in SX+RAD were significantly older (mean +/-SEM 12.72 +/-3.36 
years) than cats in NONE (9.69+/- 0.54 years) and cats in SX (9.49 +/- 0.29 years) 
(P=0.05, ANOVA).  There was no association between age and outcome (alive, dead, 
or euthanasia) (95% CI proportional odds ratio 0.97-1.05)  
The estimated rates and corresponding transition probability matrices are given 
in Table 4-1 and Figure 4-2, respectively. SX and SX+RAD had similar rates and 
probabilities of first recurrence.  A comparison of absorption after the first recurrence 
was not possible. Absorption after the first recurrence for SX+RAD would appear 
infrequent and an estimate was not attained in this group, probably due to the small 
sample size. SX and SX+RAD had similar rates and probabilities of two or more 
recurrences, however, SX+RAD had a much higher rate of absorption after two or 
more recurrences. NONE were more likely to be euthanized while SX and SX+RAD 
were likely to die.  
The estimated duration in ENTRY was not significantly different between 
groups (Table 4-2 and Figure 4-3). The estimated duration in RECURR1 and the 
estimated duration in RECURR2+ were significantly shorter for SX than SX+RAD 
(P<0.001, t-test; P<0.01, t-test, respectively). The mean expected survival was 
significantly shorter for NONE than SX than SX+RAD (P<0.05, ANOVA).   
For NONE, simulation resulted in 26.3% absorptions by death and 73.7% by 
euthanasia, SX had 67.4% absorptions by death and 32.6% by euthanasia and 
SX+RAD had 82.2% absorptions by death and 17.8% euthanasia. 
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Table 4-1 Estimated transition rates. 
 
 
Initial State Transition rates  
(events/animal-months) 
NONE Recurr 1 Recurr2+ Death  Euth 
Disease 0 0 0.0717 0.2073 
Recurr1 - 0 0 0 
Recurr2+ 0 - 0 0 
     
SX Recurr 1 Recurr2+ Death  Euth 
Disease 0.1165 0 0.0546 0.0901 
Recurr1 - 0.1410 0.0694 0.0073 
Recurr2+  - 0.0976 0.1141 
     
SX+RAD Recurr 1 Recurr2+ Death  Euth 
Disease 0.1444 0 0.1385 0 
Recurr1 - 0.1301 0 0 
Recurr2+ 0 - 0.6250 0.3074 
     
ALL Recurr 1 Recurr2+ Death  Euth 
Disease 0.1195 0 0.0638 0.1439 
Recurr1 - 0.0639 0.0694 0.2202 
Recurr2+ 0 - 0.1357 0.1254 
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ENTRY RECURR1 RECURR2+ DEATH EUTH
ENTRY 0.7436 0 0 0.0692 0.1872
RECURR1 0 1 0 0 0
RECURR2+ 0 0 1 0 0
DEATH 0 0 0 1 0
EUTH 0 0 0 0 1
    =       
NONEP
ENTRY RECURR1 RECURR2+ DEATH EUTH
ENTRY 0.7507 0.1100 0 0.0531 0.0862
RECURR1 0 0.1912 0.1315 0.6700 0.0073
RECURR2+ 0 0 0.7992 0.0930 0.1078
DEATH 0 0 0 1 0
EUTH 0 0 0 0 1
    =       
SXP
ENTRY RECURR1 RECURR2+ DEATH EUTH
ENTRY 0.7632 0.1345 0 0.1293 0
RECURR1 0 0.8780 0.1220 0 0
RECURR2+ 0 0 0.2707 0.4647 0.2646
DEATH 0 0 0 1 0
EUTH 0 0 0 0 1
    =       
SX+RADP
 
 
Figure 4-2 Transition probability matrices (P) for 59 cats that did not receive surgical 
treatment (NONE) for vaccine-associated sarcoma, 208 cats that received surgery 
alone (SX) and 27 cats undergoing surgery and radiation treatment (SX+RAD).   
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Table 4-2 Mean (95% CI) residence times (months) generated by Monte Carlo 
simulation of the Markov model starting in ENTRY. 
 
 
Treatment group Transition state Expected survival 
NONE Entry Recurr1 Recurr2+  
Entry 3.88 
(3.62-4.15) 
- - 3.88 
(3.62-4.15) 
SX Entry Recurr1 Recurr2+  
Entry 4.25 
(3.45-4.75) 
0.70 
(0.57-0.83) 
0.37 
(0.07-0.66) 
5.32 
(4.73-5.91) 
SX+RAD Entry Recurr1 Recurr2+  
Entry 4.00 
(3.43-4.57) 
5.31 
(4.25-6.37) 
0.83 
(0.68-0.98) 
10.14 
(8.92-11.35) 
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Figure 4-3 Estimated duration spent in transient states and mean expected survival for 
each treatment group. Duration across states with the same letter are not significantly 
different.  SX+RAD** had significantly longer mean expected survival (10.14 
months) than SX* (5.32 months) and NONE (3.88 months). 
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The transient analysis illustrated the successive probabilities over time of being 
in the transient states (Figure 4-4). Note that although the overall expected survival  
for SX is longer than NONE, the course of the disease for SX is similar to that of 
NONE, except for a small proportion of time likely to be spent in recurrence states.  In 
contrast, the course of the disease for SX+RAD is prolonged by the increased 
probability of transition into recurrence states.   
Sensitivity analysis showed predictable behavior of the model and estimation 
of mean expected survival for all groups.  As the probability of residing in the 
transient states increased, there was a corresponding increase in mean expected 
survival (Figure 4-5).  The mean expected survival remained consistently higher for 
SX+RAD than SX and NONE.  Interestingly, all groups behaved similarly with 
minimal increases in expected survival until the probability of remaining in the 
adjusted transient state reach 0.7 or more. For NONE, the sensitivity analysis was 
intuitive since the probability of remaining in ENTRY had the only impact on 
expected survival.  For SX, the slope of the sensitivity curve was steepest for ENTRY, 
thus increments in the probability of remaining in ENTRY had the most impact on 
expected survival.  Increments in the probability of remaining in RECURR2+ had the 
least impact on expected survival.  For SX+RAD, increments in the probability of 
remaining in ENTRY also had the most impact on expected survival while the 
probability of remaining in RECURR1 and in RECURR2+ had similar but lesser 
effects.  
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Figure 4-4 Transient analysis with probabilities of being in any state at any given 
cycle (time) conditional in starting in ENTRY.  
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Figure 4-5 Impact of increasing probability of residing in transient states ENTRY, 
RECURRENCE1 (REC1) and RECURRENCE2+ (REC2) on mean expected survival 
for each treatment group. 
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4.4 Discussion 
This study allowed an integrated assessment of the progression and prognosis of cats 
treated for VAS by surgery alone or with radiation.  For this cohort, surgery and 
radiation resulted in the longest predicted expected survival with a mean of 10 months. 
The analysis clearly shows it was the prolonged time after treatment and recurrences 
that these cats experienced contributed to extended expected survival. 
Interestingly, the time to first recurrence was not different between surgery or 
surgery plus radiation and was also similar to the time to death or euthanasia for cats 
not receiving surgery.  Cats treated for initial recurrence with surgery alone were 
likely, on average, to take less than one month to develop subsequent recurrence(s), 
however; repeated surgery did prolong their life over no surgical treatment.  There was 
considerable mortality associated for cats treated for initial recurrence with surgery 
alone. Cats undergoing surgery and radiation were likely to take considerably longer 
to develop a second recurrence than cats undergoing surgery alone, on average, nearly 
five and a half months.  The time between recurrences prolonged the expected survival 
for SX+RAD over other treatment protocols. 
The estimated expected survival with treatment protocols in this study were 
similar to reported median and mean survival estimated by Kaplan-Meier product limit 
methods in one study of 45 cats (Davidson, et al., 1997).  Davidson reported mean and 
median tumor-free interval and survival for cats undergoing a single surgical excision 
of 16 months each; mean tumor-free interval and survival for cats undergoing two or 
more surgical excisions of 11 and 12.6 months respectively, and mean tumor-free 
interval and survival for cats undergoing surgery and radiation (cobalt 60 radiation or 
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iridium brachytherapy) of 6.7 and 8.2 months respectively.  The estimated mean 
expected survival with treatment protocols is the current study are however, 
considerably shorter than median survival (no means were given) reported by Cronin, 
Bregazzi, Cohen, and Kobayashi, however treatment protocols are clearly different. 
Cronin reported on 33 cats that had cobalt 60 radiation treatment with 48 Gy in 16 
daily 3.0 Gy fractions followed by surgical excision two to four months after 
completion of radiation treatment (Cronin, et al., 1998). Some cats also received 
doxorubicin. Cronin reported a median disease-free interval and median survival for 
cats undergoing radiation and surgery (and sometimes chemotherapy) of 13.3 and 20 
months respectively. Kobayashi used data from Cronin’ study and data from an 
additional 59 cats (total of 92 cats) that received the same preoperative cobalt therapy 
(Kobayashi et al., 2002).  Some cats also received doxorubicin or carboplatin.  
Kobayashi reported median time to death, local recurrence or metastasis (whatever 
occurred first in each cat) for cats undergoing radiation and surgery (and sometimes 
chemotherapy) of 19.4 months. Bregazzi reported the results for 25 cats that had 
surgical excision followed by electron beam radiation treatment with approximately 
57 Gy delivered in 19 fractions of  6mV photons or 5-12 MeV electrons, depending on 
the thickness of the tumor (Bregazzi, et al., 2001). Some cats also received 
doxorubicin. Bregazzi reported median survival for seven cats undergoing surgery and 
radiation of  20.8 months. The median disease-free interval was not estimable for these 
cats. Bregazzi reported median disease-free interval and survival for 18 cats 
undergoing surgery, radiation and chemotherapy of 22 and 28 months respectively. 
Cohen reported the results for 78 cats that had surgical excision followed by electron 
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beam radiation treatment with 13 fractions of 400cGy treated at 4MeV, 6MeV or 8 
MeV electrons, depending on the thickness of the tumor (Cohen, et al., 2001). Some 
cats also received doxorubicin or cyclosphosphamide. Cohen reported median disease-
free interval and survival for cats undergoing surgery and radiation (and sometimes 
chemotherapy) of 13.5 and 24 months respectively.   
Since categorization of treatment protocols and groups are not the same for the 
current study or these previous studies, direct comparisons are difficult. More 
importantly, it must be realized that estimates in the current study are based on 
different methodology, which requires different assumptions. Direct comparisons 
should be discouraged.  Instead, appropriate interpretation and validation of each 
estimate should be explored. 
Generation and comparison of survival functions by Kaplan-Meier product 
limit estimation is useful for hypothesis testing although it does not allow modeling of 
regression covariates. Instead, stratification of data on possible covariates is performed 
(Lee, 1992b).  Kaplan-Meier product limit estimation is based on an underlying 
assumption of non-informative censoring (Lee, 1992a). Unfortunately, Kaplan-Meier 
estimation is sensitive to classification of observations, which makes comparisons 
between studies unreliable (Hosgood and Scholl, 2000).  In particular, there is no 
ability to accommodate observations from euthanized animals other than equating 
them with death (Davidson, et al., 1997, Barber, et al., 2000, Hershey, et al., 2000, 
Cohen, et al., 2001).  Investigators commonly report median survival times as a 
summary measurement of their data (Davidson, et al., 1997, Barber, et al., 2000, 
Hershey, et al., 2000, Cohen, et al., 2001, Kobayashi, et al., 2002).  The median 
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survival time does not convey prognostic or predictive information. The median 
survival time is the time at which the survival function transects the 0.5 quartile of the 
probability of survival. This is not equal to the arithmetic median and varying 
proportions of the cohort may be alive or dead at this point. In some cohorts, a median 
may be inestimable if the survival function does not cross this quartile (Lee, 1992a). 
The median is substantially affected by the slope of the early part of the survival 
function and hence the early experience of the cohort.  The median does not reflect the 
shape of the survival function, which is better described by the mean. The mean is 
equivalent to the area contained under the survival function and is only equal to the 
arithmetic mean if all observations are complete (Lee, 1992a). Unfortunately, several  
previous investigators of VAS (Cronin, et al., 1998 Bregazzi, et al., 2001, Cohen, et 
al., 2001, Kobayashi, et al., 2002) did not report the mean survival times calculated  
from the estimated survival functions. 
In the clinical setting, veterinarians and owners require information on the 
disease course, the prognosis and the probability of the pet dying.  This information is 
important for individual treatment selection and decision-making.  The survival 
function cannot easily provide this information and it is the hazard function that 
describes the conditional risk of dying (Silverstein, et al., 1988). The hazard rate 
describes the conditional probability of dying after time t, given that the subject has 
survived to time t. The hazard rate depends on both the survival rate and the rate of 
change (slope) of the survival curve (Silverstein, et al., 1988).  An often-overlooked 
limitation of survival curve analysis results from inappropriately interpreting the 
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survival function of a group after a time interval as the probability of future survival 
for an individual who has survived to that time period (Silverstein, et al., 1988).   
Estimation of expected survival from a Markov model is akin to estimation of 
survival from the hazard function since the transition probability (to death) represents 
the future probability of death, given the current state (alive at time t), which defines 
the hazard rate.  Estimation of expected survival from a Markov model should be 
thought of as an extrapolated survival under the assumption that the constant transition 
probabilities will continue to apply in the future (Silverstein, et al., 1988). The term 
expected survival is used in this paper to convey that it is a projected estimate of 
survival. Thus, expected survival is an estimate based on the probability of dying 
gleaned from the cohort. This is in contrast to the estimate of median survival time 
derived from a survival function, which is a summary statistic of the survival function 
of the cohort.  
While the probability matrix summarizes transition probabilities of the cohort, 
the transient analysis allows prediction or prognosis for an individual subject, given 
their starting state, current state and cycle (Urakabe, et al., 1975, Silverstein, et al., 
1988, de Kruyk, 1998 #149, Kuo, et al., 1999, Bauerle, et al., 2000, Myers, et al., 
2000).  This is useful information for individual decision-making (Urakabe, et al., 
1975, Silverstein, et al., 1988). For example, given an owner elected surgery and 
radiation treatment (and their cat started in ENTRY), if their cat is alive (ENTRY) 
after the first treatment at 5 months, the probability that it will continue to be alive or 
develop recurrence as opposed to dying or requiring euthanasia is 0.5.  
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The validity of the estimate of expected survival derived from the Markov 
analysis is dependent on many factors. Any time a model is used, assumptions are 
made and acceptance of the model and its limitations are required (de Kruyk, et al., 
1998, Sendi, et al., 1999). In this case, assumption of time homogeneity and a 
memory-less process are fundamental.  For the purpose of this study, these 
assumptions were deemed plausible.  It is unlikely that environmental conditions 
influenced transition probabilities over the course of the study.  Violation of time-
homogeneity is a problem in chronic human disease since aging and development of 
concurrent illnesses have a significant influence on mortality rate (Beck, et al., 1982). 
Whether this occurs is veterinary populations is undetermined. Yearly increments in 
age were not associated with outcome in the cats of this study and age was considered 
unlikely to confound the transition probabilities to absorbing states. There was most 
concern that age may be associated with euthanasia but this was not apparent. 
Although the mean age of SX+RAD cats was older than the other cats, this does not 
imply any association of age and treatment but merely helps to describe the 
characteristics of the group. Sequential recurrence states were included since 
development of recurrence is probably more likely if previous recurrence had 
occurred. In addition, absorption rates may be different from the recurrence states.   
The precision of estimates of transition probabilities is inherent to the validity 
of the model and subsequent estimates of expected survival.  Although the 
probabilities used in the Markov model were calculated from a large sample with 
many subject-time interval observations, precision may be lost when the incidence rate 
of transitions per subject time is used to approximate the probability. The incidence 
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rate can give an approximation of the probability when rates are small (Silverstein, et 
al., 1988). In this study, the exact probability was calculated from the rate was used to 
avoid any imprecision. The SX+RAD group had the smallest number of observations 
and estimates may have been imprecise, leading to possible inflation of the expected 
survival. Estimates of expected survival are most influenced by imprecision when the 
probability estimates are small (Silverstein, et al., 1988).  An alternative would have 
been to collapse the treatment groups to increase the number of observations as long 
as this did not violate the Markovian assumption.  However, collapsing groups also 
risks loss of information.  A reduced treatment model was explored where 
observations for surgery for cats in SX+RAD were included in estimation of 
probabilities for the SX group.  There was no gain in information for the comparison 
between NONE and SX, probably since the additional information gained for SX was 
small.  There was, of course, loss of information for the SX+RAD group. The 
behavior of the model described by transient and sensitivity analyses was very similar 
to the current investigation. No advantages were seen with use of this model, hence 
the results are not reported.  
The SX+RAD model did perform as predicted during the sensitivity analysis. 
Sensitivity analysis provides a tool for studying the behavior of the model (Sendi, et 
al., 1999, Aoki, et al., 2000). While it does not provide any confidence statement about 
the results, it may reveal inconsistencies in the model, which reflect violation of 
assumptions or other problems such as imprecise estimates or flawed data (Lawless 
and Yan, 1993, Cowen, et al., 1994, Sendi, et al., 1999, Aoki, et al., 2000, Jacobs, et 
al., 2001). One-way sensitivity analysis was easily computed in this study and no 
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major deviances were detected.  Manipulation of two or more variables together 
becomes complex because a two or more dimensional polyhedron rather than a single 
line describes the range of values (Jensen and Bard, 2002b). It must be remembered 
however, that one-way sensitivity analysis gives limited estimation of uncertainly 
because the results are a function of the entire matrix and not just a single probability 
(Sendi, et al., 1999). 
Another application of sensitivity analysis is to predict changes in outcome 
with manipulation of probabilities in the model.  Expected survival increased as the 
probability of staying in ENTRY, RECURR1 and RECURR2+ increased. The 
probability of staying in these states, in theory, represented a curative treatment.  It 
was noted however, that expected survival did not increase appreciably until the 
probabilities of staying in these states increased above 0.8.  Thus, unless treatment 
would result in at least an 80% chance of being a curative procedure, it would not 
prolong expected survival.  This information has importance in decision-making and 
also in developing new treatment strategies.   
Estimates of state durations and expected survival derived from matrix 
solution, Monte Carlo simulation or cohort simulation give similar results if equivalent 
transition probabilities and distributions are used, and if a large number of life 
histories are generated with the Monte Carlo approach (Briggs and Sculpher, 1998, de 
Kruyk, et al., 1998). The variance of these estimates may however vary. Monte Carlo 
simulation was used in this study because it has the advantage of generating variances 
very easily, which can be reduced by increasing the number of simulations. Monte 
Carlo simulation is however, a time-consuming process. Matrix solution is simple and 
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gives an exact solution. Matrix solution could have been used in this study since the 
stationary probability matrix described the model. However, matrix solution invariably 
generates large variance estimates, of the magnitude of the estimated state durations, 
which can prohibit comparisons (Silverstein, et al., 1988).   Cohort simulation was 
used for the sensitivity analysis since it generates an estimate rapidly. However, it is 
restrictive since it does not generate a variance estimate and is less suitable when 
comparisons between estimates are required (Briggs and Sculpher, 1998).   
There is discrepancy among the previous studies on whether radiation in 
conjunction with surgery is beneficial. Our results would agree with that of Cohen 
(Cohen, et al., 2001) and support beneficial effects of radiation. No attempt was made 
in our study to examine adequacy of surgical excision or categorize cats according to 
number of procedures (Davidson, et al., 1997). Comparing cats that had one versus 
two or more procedures, or adequate versus inadequate resection would appear futile 
(Davidson, et al., 1997, Cohen, et al., 2001).  Instead, the number of surgical 
procedures was incorporated into the model through the sequence of recurrence states.  
This has the advantage of viewing these events in context of the complete process.  
The transient analysis highlighted how the time to and between recurrences is 
principal to the expected survival of treated cats.  
Treatment protocols were not applied as part of a randomized clinical trial in 
this study or previous studies. Hence, bias is introduced in the number and type of 
treatments performed and hypothesis testing of protocols is invalid. All results must be 
interpreted in light of this and any statistical testing should be used to enhance the 
description of the groups rather than the basis for decisive conclusions. It would be 
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intuitive that cats undergoing one procedure would have a better prognosis than those 
undergoing two or more (Davidson, et al., 1997, Cohen, et al., 2001).  Cats requiring 
one procedure are likely to have had easily resectable disease and consequently did not 
require multiple procedures to attempt to completely excise the lesion.  In contrast, it 
is likely that radiation is recommended and applied to cats with non-resectable or 
incompletely resected lesions, that is, the worst cases.  In addition, it takes a certain 
commitment by an owner to elect this treatment protocol (cost, time).  In light of this 
bias, the benefit of adjunct radiation therapy suggested by this study and Cohen’s,  
may be more encouraging since it was possibly selected for cats with the worst 
lesions.   
Euthanasia represents premature absorption from the process.  Euthanasia 
represents a complicated informative-censoring situation where the subjects fail due to 
a secondary outcome of interest (euthanasia) that causes them to be censored 
according to the primary outcome of interest (death) (Lagakos, 1979). Euthanasia also 
represents a competing risk (Llorca and Delgado-Rodriguez, 2001). This situation 
becomes complicated because the objective for most competing risks is to estimate the 
time of failure from a particular cause when other causes of failure are not in effect.  
However, in this case, the complete observation of the survival time of interest is an 
unachievable event (Lagakos, 1979). In the Markov model, this would require 
estimating the transition probability from euthanasia to death which is obviously 
impossible.  
Markov modeling has the ability to cope with informative censoring.  If the 
data is dense enough, data that fails to meet the assumption of non-informative 
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censoring can be handled by definition of additional absorbing states (Hillis, et al., 
1986, Diggle and Kenward, 1994).  The impact euthanasia has on the Markov process 
can be visualized in the transient analysis.  By including euthanasia as a separate 
absorbing state, its probability is acknowledged and the absorption can be noted. 
However, since it becomes an identified endpoint, and there is no estimate of the 
transition from euthanasia to death, it truncates the estimates of expected survival as 
any termination would.   
Despite, the inadequacies of a historical treatment cohort, this study clearly 
showed that commitment to treatment and retreatment did extend the expected 
survival of cats with VAS.  Repeated treatment with surgery or surgery with radiation 
did extend the expected survival of cats over no surgical treatment.  
4.5 Notes 
a MatLab 6, The Mathworks Inc. 
 
bMarkov Chain Add-in for  Excel Spreadsheets, Jensen, P.A., Bard, J. Operations 
Research Models and Methods, University of Texas. 
 
cSAS V 8.0, SAS Institute, Cary, NC. 
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SUMMARY 
Investigators of veterinary clinical studies apply a limited array of statistical 
methods and almost exclusively use Kaplan-Meier product limit methods for analysis 
of time-event data.  Unfortunately, the intent of the analysis or the assumptions 
required are often inappropriate for the methods applied. Application of survival 
analysis to clinical studies restricts the observation of the disease to two states – alive 
or dead (or other outcome), and restricts the analysis to determining the differences 
between survival functions for the entire study period.    
Investigators in veterinary clinical studies continue to struggle with 
classification of observations from animals that are euthanized, as evident by the array 
of classification protocols used, ignorance of the problem, and certain comments made 
by investigators. The first study showed that Kaplan-Meier product limit estimation is 
sensitive to classification of observations and provided unstable estimates of median 
and mean survival time, particularly when there was a high frequency of right-
censored observations. Of particular concern was the result of reversed ranking of 
point estimates of median survival time by use of different classification protocols 
(ones that are currently used by other investigators), which may influence 
investigators conclusions and decision-making.   
Modeling the progression of canine lymphoma was accomplished using a time-
homogenous Markov chain. Estimates of expected survival were obtained and 
appeared plausible. Estimates of survival could be partitioned according to the time 
spent in different health states, conditional on the starting state of the animal. In 
addition, the cause of loss could be identified.  This information is useful for 
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individual decision-making.  The estimates of survival obtained by matrix solution and 
Monte Carlo simulation were similar and appeared reliable.  
A 5-state Markov model was used to compare progression of vaccine-
associated sarcoma in a cohort of 294 cats receiving different treatments.  Transition 
probabilities were derived from exponential transformation of incidence rates. 
Separate P matrices were constructed for each treatments – NONE (no surgery), SX 
(surgery) and SX+RAD (surgery and radiation). Estimates of time spent in transient 
states and life expectancy (expected survival) were generated by Monte Carlo 
simulation for each treatment. SX+RAD prolonged life expectancy significantly 
longer than SX than NONE.  The time spent in transient states of recurrent disease 
contributed to the prolonged life expectancy.  Commitment to repeated treatment with 
surgery, or with surgery and radiation, is required to prolong the life expectancy of 
cats with vaccine-associated sarcoma.   
An important distinction must be made between interpretations of Markov 
analysis and traditional survival analysis.  The analysis of a survival curve provides 
information best suited to hypothesis testing concerning factors that influence the 
survival of stratified groups, whether this is a treatment or disease characteristic. The 
Markov analysis, in contrast, provided prognostic data best suited to facilitate 
individual decision-making.  
Although Markov modeling has its own set of restrictions and limitations, its 
application to veterinary clinical studies has merit and allows an array of analyses.  
The work of this dissertation would support further exploration of this methodology 
for evaluation of veterinary clinical studies. Acquisition of prospective data with 
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random variables would be a useful step. Acquiring quality data with the intent of 
Markov analysis is important to continued exploration and validation of Markov 
models for veterinary clinical data.  More rigorous testing of the time homogeneity 
assumption and application of more advanced techniques that include fixed and time-
dependent covariates would be an obvious next step.  
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APPENDIX I DERIVATION OF THE N MATRIX  
 
Briefly, when Q is multiplied by itself, Q x Q = Q2, the product matrix is 
composed of the probabilities of the animal being in each transient state after two 
cycles (Beck and Pauker, 1983, Brown and Brown, 1990b).  When this matrix is 
multiplied again by Q, the elements of Q3 represent the probabilities of being in a 
specified transient state after three cycles.  This process can be repeated indefinitely; 
after each cycle the entries in Q will decrease because the Markov model has 
absorbing states and eventually all subjects will be absorbed. Thus Q  as n gets 
very large and eventually no subjects are in a transient state.  Because the limit of Q
0→n
2 3+ Q + ...
n 
approaches a zero matrix, the sequence I  is bounded and represents 
a matrix of life expectancies. The I (identity) matrix is analogous to giving a subject a 
one unit incremental utility for starting in a particular transient state.  The sum (S) is 
itself a matrix of the same dimensions as Q. Thus S  If the 
following manipulations are performed, 
2 3+Q + Q + Q + ...
= I +Q + Q
 
( ) ( ) ( )
( ) (
( )n
=
= −
=
2 3 n-1
2 3 n-1 2 3 n
S I - Q I +Q + Q + Q + ...Q I - Q
I +Q + Q + Q + ...Q Q + Q + Q + ...Q
I - Q
)  
Since Qn approaches zero, ( )− =Q IS I .   
Because the inverse of ( )−I Q , ( )′−I Q exists, multiplying the equation by the 
inverse gives  
 139
( )( ) ( )
( )
′ ′− =
′∴
S I Q I - Q I I - Q
S = I - Q
 
Thus S, is the sum of the powers of Q, is equal to the inverse of I-Q or N (the 
fundamental matrix of a Markov chain).  The elements of N are seen as the expected 
residence time before absorption given starting the chain in either row of N. 
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APPENDIX II DERIVATION OF THE V MATRIX  
 
If survival is considered as a two state Markov chain, and p is the probability 
of death, 1-p is the probability of surviving during that cycle. The transition matrix is  
1
0 1
p p− 
 . Since survival is the waiting time for the first occurrence of death, the 
number of cycles that a subject survives can follow a geometric distribution, the 
simplest waiting time distribution (Casella and Berger, 1990, Hogg and Craig, 1995). 
For the geometric distribution,  
( -1)Prob (surviving X cycles= ; )= (1- ) xx p p p  where x =1,2,3,4… and       
1EX
p
=  and 21Var pX p
−= .  
The variance can be rewritten as 2 2 2
2 1 1 (2 )pX p 2
1Var
p p p p
−= − = − − .    
Since the expected survival time (time to death) is given by the inverse of the 
probability of death, this can be likened to taking the inverse of the Q matrix to 
determine the N matrix (Beck and Pauker, 1983).  If we let 1n
p
= , then  
2 1 2Var (2 ) (2 1) 2X n n n n n− n= − − = − −   
For the purpose of calculation of the variance of the N matrix with more than 
two states, n is replaced by vectors for each starting state such that .  2( - ) -=V N 2N I N
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